WO2007029376A1 - Orally rapidly disintegrating tablet - Google Patents
Orally rapidly disintegrating tablet Download PDFInfo
- Publication number
- WO2007029376A1 WO2007029376A1 PCT/JP2006/309706 JP2006309706W WO2007029376A1 WO 2007029376 A1 WO2007029376 A1 WO 2007029376A1 JP 2006309706 W JP2006309706 W JP 2006309706W WO 2007029376 A1 WO2007029376 A1 WO 2007029376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- parts
- granulated particles
- magnesium
- rapidly disintegrating
- Prior art date
Links
- 239000011361 granulated particle Substances 0.000 claims abstract description 137
- 210000000214 mouth Anatomy 0.000 claims abstract description 43
- 239000004480 active ingredient Substances 0.000 claims abstract description 35
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 32
- 239000000126 substance Substances 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 239000011230 binding agent Substances 0.000 claims abstract description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 24
- 239000000314 lubricant Substances 0.000 claims abstract description 19
- 239000004570 mortar (masonry) Substances 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 9
- 239000011246 composite particle Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 7
- 238000007906 compression Methods 0.000 claims abstract description 6
- 230000006835 compression Effects 0.000 claims abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 144
- 238000002156 mixing Methods 0.000 claims description 77
- 235000019359 magnesium stearate Nutrition 0.000 claims description 72
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 54
- 239000001913 cellulose Substances 0.000 claims description 38
- 235000010980 cellulose Nutrition 0.000 claims description 35
- 229920002678 cellulose Polymers 0.000 claims description 35
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 32
- 229960000913 crospovidone Drugs 0.000 claims description 32
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 32
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 32
- 229920002472 Starch Polymers 0.000 claims description 28
- 239000007884 disintegrant Substances 0.000 claims description 25
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 23
- 239000008187 granular material Substances 0.000 claims description 23
- 239000008107 starch Substances 0.000 claims description 22
- 235000019698 starch Nutrition 0.000 claims description 22
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 20
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 20
- 238000001694 spray drying Methods 0.000 claims description 20
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 19
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 19
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 19
- 229950008138 carmellose Drugs 0.000 claims description 19
- 229930006000 Sucrose Natural products 0.000 claims description 18
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 17
- 239000011777 magnesium Substances 0.000 claims description 17
- 229910052749 magnesium Inorganic materials 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 16
- 235000010355 mannitol Nutrition 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 16
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims description 15
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 15
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 14
- 239000000194 fatty acid Substances 0.000 claims description 14
- 229930195729 fatty acid Natural products 0.000 claims description 14
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000811 xylitol Substances 0.000 claims description 14
- 235000010447 xylitol Nutrition 0.000 claims description 14
- 229960002675 xylitol Drugs 0.000 claims description 14
- 229920002261 Corn starch Polymers 0.000 claims description 13
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 13
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 13
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 13
- 229940100486 rice starch Drugs 0.000 claims description 13
- 239000005720 sucrose Substances 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 239000008120 corn starch Substances 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 238000000748 compression moulding Methods 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 235000010449 maltitol Nutrition 0.000 claims description 10
- 239000000845 maltitol Substances 0.000 claims description 10
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 10
- 229940035436 maltitol Drugs 0.000 claims description 10
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 9
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 9
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 9
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 9
- 239000001095 magnesium carbonate Substances 0.000 claims description 9
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 229940083542 sodium Drugs 0.000 claims description 8
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 claims description 7
- 239000004386 Erythritol Substances 0.000 claims description 7
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 239000000378 calcium silicate Substances 0.000 claims description 7
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 7
- 235000012241 calcium silicate Nutrition 0.000 claims description 7
- 235000019414 erythritol Nutrition 0.000 claims description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 7
- 229940009714 erythritol Drugs 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 7
- 239000000395 magnesium oxide Substances 0.000 claims description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- 235000012245 magnesium oxide Nutrition 0.000 claims description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 7
- 244000215068 Acacia senegal Species 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 6
- 241000416162 Astragalus gummifer Species 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920000084 Gum arabic Polymers 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229920001800 Shellac Polymers 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000000205 acacia gum Substances 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 6
- 235000013539 calcium stearate Nutrition 0.000 claims description 6
- 239000008116 calcium stearate Substances 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 6
- 239000000347 magnesium hydroxide Substances 0.000 claims description 6
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 6
- 229920001592 potato starch Polymers 0.000 claims description 6
- 239000004208 shellac Substances 0.000 claims description 6
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 6
- 235000013874 shellac Nutrition 0.000 claims description 6
- 229940113147 shellac Drugs 0.000 claims description 6
- 235000010356 sorbitol Nutrition 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 229920001615 Tragacanth Polymers 0.000 claims description 5
- RKFMOTBTFHXWCM-UHFFFAOYSA-M [AlH2]O Chemical compound [AlH2]O RKFMOTBTFHXWCM-UHFFFAOYSA-M 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 235000010419 agar Nutrition 0.000 claims description 5
- 229940023476 agar Drugs 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 235000012254 magnesium hydroxide Nutrition 0.000 claims description 5
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000391 magnesium silicate Substances 0.000 claims description 5
- 235000019792 magnesium silicate Nutrition 0.000 claims description 5
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 239000000454 talc Substances 0.000 claims description 5
- 229910052623 talc Inorganic materials 0.000 claims description 5
- 235000010487 tragacanth Nutrition 0.000 claims description 5
- 239000000196 tragacanth Substances 0.000 claims description 5
- 229940116362 tragacanth Drugs 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 239000000440 bentonite Substances 0.000 claims description 4
- 229910000278 bentonite Inorganic materials 0.000 claims description 4
- 235000012216 bentonite Nutrition 0.000 claims description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 235000001465 calcium Nutrition 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 claims description 3
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920003124 powdered cellulose Polymers 0.000 claims description 3
- 235000019814 powdered cellulose Nutrition 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims 2
- AEHFKTQRPMZBBA-UHFFFAOYSA-H aluminum dicalcium diphosphate Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2].P(=O)([O-])([O-])[O-].[Al+3] AEHFKTQRPMZBBA-UHFFFAOYSA-H 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 42
- 239000000203 mixture Substances 0.000 abstract description 42
- 239000003814 drug Substances 0.000 abstract description 21
- 229940079593 drug Drugs 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000000465 moulding Methods 0.000 abstract description 4
- 238000010410 dusting Methods 0.000 abstract 1
- 230000001050 lubricating effect Effects 0.000 abstract 1
- 238000007493 shaping process Methods 0.000 abstract 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 54
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 29
- 229960001138 acetylsalicylic acid Drugs 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 27
- 229960005489 paracetamol Drugs 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 229940032147 starch Drugs 0.000 description 19
- 229960001855 mannitol Drugs 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 235000019700 dicalcium phosphate Nutrition 0.000 description 11
- 229960004793 sucrose Drugs 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 239000007921 spray Substances 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 229960001375 lactose Drugs 0.000 description 7
- 229960002160 maltose Drugs 0.000 description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 7
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 229960002737 fructose Drugs 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 229960002920 sorbitol Drugs 0.000 description 6
- 229940074410 trehalose Drugs 0.000 description 6
- 229940100445 wheat starch Drugs 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 229940078456 calcium stearate Drugs 0.000 description 5
- 210000002858 crystal cell Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 229940014259 gelatin Drugs 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 229950008882 polysorbate Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 229920002675 Polyoxyl Polymers 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 229940033134 talc Drugs 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000004927 clay Substances 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229940118662 aluminum carbonate Drugs 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229940095672 calcium sulfate Drugs 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 239000007765 cera alba Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940124568 digestive agent Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940100515 sorbitan Drugs 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- IKEHOXWJQXIQAG-UHFFFAOYSA-N 2-tert-butyl-4-methylphenol Chemical compound CC1=CC=C(O)C(C(C)(C)C)=C1 IKEHOXWJQXIQAG-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920003115 HPC-SL Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000115721 Pennisetum typhoides Species 0.000 description 1
- 235000007195 Pennisetum typhoides Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000008515 Setaria glauca Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 241001080519 Zera Species 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- DCOLOVHTJKNUOI-UHFFFAOYSA-J [OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++] Chemical compound [OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++] DCOLOVHTJKNUOI-UHFFFAOYSA-J 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000004645 aluminates Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- WKWXUDDFKKQZNC-UHFFFAOYSA-J aluminum sodium carbonic acid hydrogen carbonate carbonate hydroxide Chemical compound [OH-].[Al+3].C([O-])(O)=O.[Na+].C([O-])([O-])=O.C(O)(O)=O WKWXUDDFKKQZNC-UHFFFAOYSA-J 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- QDOXWKRWXJOMAK-UHFFFAOYSA-N dichromium trioxide Chemical compound O=[Cr]O[Cr]=O QDOXWKRWXJOMAK-UHFFFAOYSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940105082 medicinal charcoal Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 235000016337 monopotassium tartrate Nutrition 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
Definitions
- the present invention relates to an intraoral rapidly disintegrating tablet having rapid and powerful disintegration property and appropriate hardness in the oral cavity, and a method for producing the same with high productivity.
- the intraoral rapidly disintegrating tablet of the present invention can be used in the field of medicine.
- Intraoral rapidly disintegrating tablets have a disintegration time of about 60 seconds or less in the oral cavity, and need to have a certain degree of hardness so that the tablets are not chipped or pulverized during manufacture or transportation. Hardness and disintegration time are contradictory elements. If disintegration time is increased, the hardness decreases, and if the hardness is increased, the disintegration time decreases. In order to solve the problem of disintegration time and hardness, several methods are known for producing a rapidly disintegrating tablet in the oral cavity, including a wet tableting method, a tableting warming method, and a direct tableting method.
- the usual preparation equipment for compression molding cannot be used, and a heating device, a humidifying device, and a drying device are required, and special equipment is required.
- the process involves processes such as humidification, warming, and drying in addition to normal compression molding, so there is a problem in productivity and it is not suitable for water-soluble active ingredients.
- a method for producing an orally rapidly disintegrating tablet by the direct tableting method can use a normal preparation facility.
- the direct tableting method it is difficult to have both moldability, moderate hardness and disintegration while increasing the content of the active ingredient, and methods for improving these are known.
- an active ingredient, spray-dried mannitol, crospovidone, and excipients that can be used for pharmaceuticals are dry mixed and then compression molded to produce an orally rapidly disintegrating tablet (see Patent Document 1). .
- Tablets made by using spray-dried mannitol suitable for direct compression and crospovidone, a super disintegrant, have moderate moldability and disintegration, but can be used as an orally rapidly disintegrating tablet.
- the tolerance between the oral disintegration time and the hardness of the obtained tablets was not always sufficient.
- Patent Document a composition for a rapidly disintegrating tablet in the oral cavity, wherein a disintegrant and an inorganic substance are uniformly dispersed in water in saccharide composite particles (Patent Document).
- Patent Documents These are granulated particles that have been spray-dried, so that they have good meterability in a compression molding machine and are particles in which disintegrants and inorganic substances are homogeneously dispersed. Indicated.
- tablets obtained by mixing and compressing active ingredients and spray-dried granules in Examples of Patent Documents 3 and 4 can obtain the desired disintegration but have insufficient hardness (30-40N), and tablet manufacture
- problems such as chipping and powdering of tablets occurred during transportation.
- the active ingredient content is high, tableting troubles such as sticking to the bag may occur.
- Patent document 1 International publication 00Z57857 pamphlet
- Patent Document 2 Japanese Patent Laid-Open No. 2001-58944
- Patent Document 3 International Publication 2005Z037319 Pamphlet
- Patent Document 4 International Publication 2005Z037254 Pamphlet
- the present invention eliminates problems that occur when the content rate of the active ingredient is high compared to the above-described prior art oral disintegrating tablets, and has sufficient hardness that does not cause problems during production and transportation and the oral cavity. It is an object of the present invention to provide an intraoral rapidly disintegrating tablet having good disintegration property and a method for producing an intraoral rapidly disintegrating tablet having high productivity.
- the "orally-fast disintegrating tablet” in the present invention means a tablet that can disintegrate rapidly in the oral cavity, for example, within 40 seconds, more preferably within 30 seconds, and even more preferably within 20 seconds.
- the oral disintegration time here is the time obtained by the conditions of the intraoral quick disintegrating tablet described later and the methods of the examples.
- the disintegration time in the oral cavity varies depending on the tablet size and tablet shape, and this is also included in the present invention.
- the tablet obtained by using the composition for rapidly disintegrating tablets in the oral cavity of the present invention has a higher active ingredient content than conventional quick disintegrating tablets, causing problems during production and transportation. It has the feature of having a good disintegration time in the oral cavity despite having a sufficient hardness. Therefore, the intraoral rapidly disintegrating tablet of the present invention obtained by blending a medicinal component with the composition is suitable for a pharmaceutical product that requires rapid or powerful disintegration in the oral cavity.
- the rapidly disintegrating tablet in the oral cavity of the present invention is (a) a structure in which an inorganic substance and a disintegrant are homogeneously dispersed in a composite particle of two or more saccharides, and further contains an active ingredient.
- B Lubricant,
- an orally rapidly disintegrating tablet comprising an active ingredient is there.
- the granulated particles used in the present invention are described below.
- the granulated particle used in the present invention is a granulated particle in which an inorganic substance and a disintegrant are homogeneously dispersed in a composite particle having mannitol and other saccharide power, or further containing an active ingredient.
- These granulated particles can be obtained by spray-drying (i) saccharides, (mouth) disintegrants, and (c) inorganic substances in water and then spray-drying, or further dispersing active ingredients and spray-drying.
- the method described in International Publication 2005Z 037319 or International Publication 2005Z037254 Therefore, it is a composition for intraoral rapidly disintegrating tablets manufactured.
- Several types of these compositions are manufactured and sold by Fuji Chemical Industry Co., Ltd. as F-M ELT [trademark], and any type can be used.
- the saccharide refers to sugar and sugar alcohol.
- the saccharide contained in the granulated particles used in the present invention is a combination of mannitol and saccharides other than mannitol.
- the saccharides other than mannitol are at least one or more selected from forces such as xylitol, sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, palatinit and palatinose.
- these saccharides those having an average particle size that are readily soluble in water can be used.
- a pharmaceutically acceptable inorganic acid containing at least one of aluminum, magnesium and strength aluminum is preferred.
- magnesium aluminate metasilicate, magnesium aluminate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate granule, hydrated talcite, calcium carbonate, calcium silicate and dried At least one selected from hydroxyaluminum gel strength, more preferably at least one selected from magnesium aluminate metasilicate, hydrated talcite, anhydrous calcium hydrogen phosphate and calcium carbonate.
- the average particle diameter of these inorganic substances is 0.1 to 100 / ⁇ ⁇ , preferably 1 to 60 / ⁇ ⁇ , and more preferably 1 to 40 m. In order to obtain a desired average particle size, a product pulverized by a conventional method can be used!
- the disintegrant contained in the granulated particles of the present invention at least one selected from crospovidone, croscarmellose sodium, low-substituted hydroxypropylcellulose, and crystalline cellulose strength is preferred. May be used alone, but it is more preferable to use them as a mixture. Of these, crospovidone and crystalline cellulose are more preferably used. When using crospovidone and crystalline cellulose, the weight ratio of crospovidone and crystalline cellulose is 5-15: 8-22, preferably 5-14: 10-22, more preferably 6-13: 12-21. Ah.
- the above disintegrant preferably has an average particle size of 0.1 to: LOO / zm, more preferably 1 to 1 in order to prevent uniform dispersibility in the composition of the present invention and roughness in the oral cavity.
- the thickness is 60 ⁇ m, more preferably 1 to 40 ⁇ m. In order to obtain a desired average particle size, those obtained by pulverization by a conventional method can be used.
- the blending amount of each component of the granulated particle of the present invention is 40 to 90 parts by weight of saccharide, 1 to 30 parts by weight of an inorganic substance, and 5 to 40 parts by weight of a disintegrant with respect to 100 parts by weight of the entire granulated particle.
- the amount is 50 to 80 parts by weight of saccharide, 2 to 15 parts by weight of an inorganic substance, and 10 to 36 parts by weight of a disintegrant with respect to 100 parts by weight of the whole granulated particles. More preferably, it is 62 to 78 parts by weight of saccharide, 3 to 8 parts by weight of an inorganic substance, and 18 to 34 parts by weight of a disintegrant with respect to 100 parts by weight of the whole granulated particles.
- the granulated particles of the present invention have a structure in which a disintegrant and an inorganic substance are homogeneously dispersed in composite particles having man-tol and saccharide power other than man-tol.
- a disintegrant and an inorganic substance are homogeneously dispersed in composite particles having man-tol and saccharide power other than man-tol.
- the granulated particles used in the present invention can contain an active ingredient described later and other ingredients that can be added to a pharmaceutical within a range not impairing the disintegration property described later.
- the amount is 0.01 to 80 parts by weight, preferably 0.05 to 70 parts by weight, more preferably 0.1 to 60 parts by weight, based on 100 parts by weight of the saccharide, inorganic substance and disintegrant. It is.
- the active ingredient is not contained in the granulated particles. Good.
- the granulated particles used in the present invention can be produced by a production method capable of obtaining desired physical properties. Commonly used methods such as a spray drying method, a fluidized bed granulation drying method, and a stirring granulation method are used. It can be produced by a wet granulation method such as a wet extrusion granulation method.
- the spray drying method is preferred from the standpoint of ease of production and easy acquisition of desired physical properties.
- the spray drying method will be specifically described below. It can be produced by spray-drying an aqueous solution or dispersion containing a saccharide, an inorganic substance and a disintegrant according to a conventional method. More specifically, after a saccharide is previously dissolved or dispersed in an aqueous solvent, a dispersion obtained by uniformly dispersing a disintegrant and an inorganic substance can be produced by spray drying.
- those containing an active component may optionally contain an active component, and are one of the other components that can be added to the pharmaceuticals described below as long as they do not impair disintegration. It can be produced by spray-drying a dispersion in which more than seeds are added and homogeneously dispersed.
- Examples of the solvent include water, ethanol, methanol and the like as long as they are pharmaceutically acceptable solvents without affecting the characteristics of the granulated particles.
- the dispersion can be prepared by a known method, and examples thereof include ordinary stirring, colloid mill, high-pressure homogenizer, ultrasonic irradiation, etc., but a method capable of highly dispersing particles in an aqueous dispersion. If it is.
- the concentration in the dispersion is not particularly limited as long as it can be spray-dried with clay of the dispersion, that is, 5 to 50% by weight, preferably 10 to 45% by weight, more preferably 25 to 45% by weight. .
- the conditions for spray drying are not particularly limited, but it is preferable to use a disk-type or nozzle-type spray dryer as the spray dryer.
- the inlet temperature is preferably about 120 to 220 ° C, and the outlet temperature is preferably about 80 to 130 ° C.
- the concentration of the solid matter in the aqueous dispersion during spray drying may be in a range that allows spray drying.
- the average particle size of the granulated particles used in the present invention thus obtained can be appropriately adjusted depending on the concentration of the aqueous solution or dispersion, the spray drying method, the drying conditions, and the like. m, preferably 5 to 300 ⁇ m, more preferably 10 to 200 ⁇ m, even more preferred 30 to 200 ⁇ m is preferable because it can prevent roughening in the oral cavity! /.
- the static specific volume of the granulated particles is preferably 1.5 to 4. Og / ml, more preferably 1.
- the granulated particles have such a static specific volume, they can be easily filled into a mortar when they are formed into tablets, so that the formulation process proceeds smoothly, the tablets are uniformly compressed, and excellent punching is achieved. Can show lockability.
- the static specific volume can be measured according to standard methods.
- the particles have good fluidity, excellent tableting properties can be shown in the formulation process.
- Examples of the lubricant used in the present invention include gum arabic powder, cacao butter, carnauba roux, carmellose calcium, carmellose sodium, caropeptide, hydrous carbon dioxide, dry hydroxide-aluminum gel, Glycerin, magnesium silicate, light anhydrous carboxylic acid, light liquid paraffin, crystalline cellulose, hydrogenated oil, synthetic aluminum silicate, sesame oil, wheat starch, white beeswax, magnesium oxide, dimethylpolysiloxane, sodium tartrate, sucrose fatty acid ester , Glycerin fatty acid ester, silicone resin, aluminum hydroxide gel, stearyl alcohol, stearic acid, aluminum stearate, calcium stearate, polyoxyl stearate, magnesium stearate, cetanol, zera Chin, Talc, Magnesium carbonate, Precipitated calcium carbonate, Corn starch, Lactose, No, Dop fat, Sucrose, Potato tempo, Hydroxy
- stearic acid magnesium stearate, calcium stearate, sucrose fatty acid ester, polyethylene glycol, sodium stearyl fumarate, talc
- the excipient, disintegration aid, and binder in the present invention are components that can improve the disintegration and moldability of the rapidly disintegrating tablet in the oral cavity of the present invention.
- Binder it is not particularly limited to these applications.
- the excipient in the present invention includes, for example, starch acrylate, L-aspartic acid, aminoethinolesnorephonic acid, aminoacetic acid, candy (powder), gum arabic, gum arabic powder, anoregic acid, sodium alginate, alpha-1 Modified starch, inositol, ethyl cellulose, ethylene acetate butyl copolymer, erythritol, sodium chloride, olive oil, kaolin, strength kaolin, casein, fructose, pumice grains, carmellose, carmellose sodium, hydrous diacid Yeast, dry hydroxyaluminum gel, dry sodium sulfate, dry magnesium sulfate, agar, agar powder, xylitol, citrate, sodium citrate, disodium citrate, glycerin, calcium glycephosphate, sodium dalconate, L- Dartami , Clay, clay grains, croscarmel
- disintegration aid in the present invention examples include adipic acid, alginic acid, sodium alginate, alpha-monoized starch, erythritol, fructose, carboxymethyl starch sodium, carmellose, carmellose calcium, carmellose sodium, hydrous silicon dioxide, Kantene, Xylitol, Guar gum, Calcium citrate, Croscarmellose sodium, Crospovidone, Synthetic aluminum silicate, Magnesium aluminate, Low-substituted hydroxypropinolecellulose, Crystalline cellulose, Crystalline cellulose 'Power normelose sodium, Wheat starch , Rice starch, cellulose acetate phthalate, dioctyl sodium sulfosuccinate, sucrose fatty acid ester, hydroxyalumina magnesium, calcium stearate , Polyoxyl stearate, sorbitan sesquioleate, gelatin, cerac, sorbitol, sorbitan fatty acid ester, talc, sodium
- the binder in the present invention includes, for example, ethyl acrylate 'methyl methacrylate copolymer emulsion, acetyl glycerin fatty acid ester, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate copolymer RS, aminoethyl sulfonic acid, candy ( Flour), gum arabic, gum arabic powder, sodium alginate, propylene glycol alginate, alpha starch starch, ester gum H, ethyl cellulose, ovata powder, hydrolyzed gelatin powder, sodium caseinate, fructose, caramel, carragham powder, carboxy Bull polymer, carboxymethylethyl cellulose, carboxymethyl starch sodium, carmellose, carmellose sodium, hydrous silicon dioxide, agar, ume powder, xanthan gum, beef tallow Oil, Guar gum, Glycerin, Synthetic aluminum silicate, Light anhydrous carboxylic acid, Hydroxy
- Polyoxypropylene Glycol, Polysorbate, Polybulacetal Jetylaminoacetate, Polybulu alcohol ( Completely saponified product), polyvinyl alcohol (partially saponified product), polyvinyl pyrrolidone, polybutene, sodium polyphosphate, D-manntol, starch, light anhydrous caustic acid, magnesium metasilicate aluminate, etc. Any of these may be used alone, but two or more of them may be blended.
- the active ingredient used in the present invention is not particularly limited, and is a central nerve agent such as a peripheral nerve agent, an antipyretic analgesic / antiinflammatory agent, a hypnotic sedative, or a neuropsychiatric agent; a skeletal muscle relaxant, an autonomic god Peripheral nerve drugs such as transdermal drugs; Cardiovascular drugs such as cardiotonic drugs, arrhythmia drugs, diuretics, vasodilators; respiratory drugs such as bronchodilators and antitussives; Digestives such as digestives, intestinal drugs, and antacids Tube drugs; metabolic drugs such as hormones, antihistamines and vitamins; anti-ulcer agents; antibiotics; chemotherapeutic agents; herbal extracts;
- a central nerve agent such as a peripheral nerve agent, an antipyretic analgesic / antiinflammatory agent, a hypnotic sedative, or a neuropsychiatric agent
- a skeletal muscle relaxant an autonomic god
- the active ingredient those processed by a known method such as coating can be used for the purpose of concealing bitterness and controlling release. Moreover, in order to release in the digestive tract, the release may be controlled by a known method. If the active ingredient is rough in the oral cavity, it can be blended in order to enhance the feeling of taking, and an average particle size of 0.1 to LOO m is preferred.
- the active ingredient should be contained in either or both of the above and outside of the granulated particles. If not included in the granulated particles, (a) the granulated particles, (b) the lubricant, and ( c) What is necessary is just to mix
- the rapidly disintegrating tablet in the oral cavity of the present invention comprises (a) granulated particles 1 to 98 with respect to 100 parts by weight of the whole tablet. Parts by weight, (b) lubricant 0.01 to 5 parts by weight, (c) at least one selected from excipients, disintegration aids and Z or binders 1 to 98 parts by weight, (d) active ingredient 0. Consists of 01-60 parts by weight.
- the whole tablet More preferably, for 100 parts by weight of the whole tablet, (a) 5 to 90 parts by weight of granulated particles, (b) 0.1 to 3 parts by weight of lubricant, (c) excipient, disintegration aid and At least one selected from Z or a binder is 5 to 90 parts by weight, and (d) the active ingredient is 0.1 to 50 parts by weight.
- the intraoral rapidly disintegrating tablet of the present invention can be blended with other components that can be blended with pharmaceuticals as long as the disintegration property is not impaired.
- Surfactants that do not impair disintegration that can be incorporated into the rapidly disintegrating tablet of the present invention include surfactants (for example, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan fatty acid ester, Polysorbate, glycerin fatty acid ester, sodium lauryl sulfate, etc.)
- Acidulants eg, citrate, tartaric acid, malic acid, ascorbic acid
- foaming agents eg, sodium bicarbonate, sodium carbonate
- sweeteners sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin
- flavoring E.g. lemon oil, orange oil, menthol, etc.
- colorants e.g. edible red No. 2, edible blue No. 2, edible yellow No. 5, edible lake dye, ferric trioxide, etc.
- stabilizers e.g. Edetate sodium, tocopherol, cyclodextrin, etc.
- the rapidly disintegrating tablet in the oral cavity of the present invention is at least one or more selected from (a) granulated particles, (b) a lubricant, (c) an excipient, a disintegration aid and Z or a binder. And (d) It can be produced by mixing the active ingredient and other ingredients that can be blended with pharmaceuticals, followed by compression molding.
- the compression molding is preferably performed by the direct tableting method.
- the tableting pressure at that time depends on the size of the tablet and can be selected within the range of tableting pressure that can be formulated.
- the other production methods include (a) granulated particles, (b) lubricant, (c) excipient, disintegration aid and at least one selected from Z or binder, and d)
- the active ingredient may be subjected to compression molding after wet granulation.
- wet granulation methods include spray drying, fluidized bed granulation drying, stirring granulation, and wet extrusion granulation.
- aging such as heating and humidification can be performed according to a conventional method to impart desired hardness' disintegration property.
- the lubricant may be mixed with other ingredients and then mixed with other ingredients, and then compression molded.
- the other It is possible to manufacture by the method of pre-coating and compression molding (external lubrication method) on the surface of the punch and the wall of the mortar without mixing with the ingredients of the mold, giving the desired hardness and disintegration can do.
- the method of applying the lubricant to the mortar can be performed by a conventionally known method or machine.
- the intraorally rapidly disintegrating tablet of the present invention has a hardness of usually 40 to 200N, preferably 40 to 150N, more preferably 40 to 120N.
- the tableting pressure can be adjusted as appropriate to achieve the above-mentioned hardness.
- a 200 mg tablet is compressed using a 8 mm diameter punch, it has a hardness of 40 to 70 N when the tableting pressure is 300 to 2400 kgf.
- the drug content has sufficient hardness, good disintegration property, and good moldability, but the properties (structure and shape) of the granulated particles are maintained. And the synergistic effect with the granulated particles due to the characteristics of certain excipients, disintegration aids and Z or the binder itself.
- the rapidly disintegrating tablet in the oral cavity of the present invention can also be used as other solid preparations such as molding into tablets other than those intended for rapid disintegrating (for example, tabletable tablets).
- the rapidly disintegrating tablet in the oral cavity of the present invention disintegrates immediately with a small amount of water, it can be used not only for pharmaceuticals but also for foods, health foods, specific function foods, pet foods, feeds and agricultural chemicals.
- Spray-dried granulation D-Mann-Toll (Pearlitol 200 SD, Roquette) 51.2 parts by weight, Xylitol (Xylit XC, Towa Kasei Kogyo Co., Ltd.) 3.2 parts by weight, Crospovidone (Coridon CL, BASF Takeda Vitamin Co., Ltd.] 7.2 parts by weight, crystalline cellulose (Ceras PH-101, manufactured by Asahi Kasei Co., Ltd.) 13.6 parts by weight, magnesium aluminate metasilicate (Neusilin UFL2, manufactured by Fuji Chemical Industry Co., Ltd.) ] 4.
- Mantol (Mannit p, manufactured by Towa Kasei Kogyo Co., Ltd.) 64 parts by weight, 4 parts by weight of xylitol, 9 parts by weight of crospovidone, 17 parts by weight of crystalline cellulose, 6 parts by weight of magnesium metasilicate aluminate in water And then spray-dried at an outlet temperature of 90 ° C using a spray dryer (L-8 type, manufactured by Okawara Kako Co., Ltd.). Good fluidity! White spherical granulated particles Got.
- the tablet After mixing 5 parts by weight of aspirin with 95 parts by weight of the granulated particles obtained in Reference Example 1, and then mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
- the tablet After mixing 20 parts by weight of aspirin with 80 parts by weight of the granulated particles obtained in Reference Example 1, and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, and the weight was 200 mg, diameter. 8mm, 9R tablets were obtained.
- the tablet is tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets with a weight of 200mg and a diameter of 8mm ⁇ 9R. It was.
- the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
- Comparative Example 1 caused tableting trouble and was unable to obtain a tablet, it can be seen that the granulated particles used in the present invention play an important role. From Examples 1 to 7 and Comparative Examples 2 to 4, by adding at least one or more selected from excipients, disintegration aids and Z or binders in the present invention, good disintegration and good molding The higher the hardness and the higher the hardness.
- Mantol 65 parts by weight, xylitol 4 parts by weight, crospovidone 9 parts by weight, crystal cell port 17 parts by weight and 5 parts by weight of anhydrous calcium hydrogen phosphate were uniformly dispersed in water, and then the outlet temperature was 90 ° using a spray dryer (L-8 type, manufactured by Okawara Chemical Co., Ltd.). Spray drying with C gave white spherical granulated particles with good fluidity.
- 70 parts by weight of the granulated particles obtained in Reference Example 2 are mixed with 10 parts by weight of aspirin and 20 parts by weight of low-substituted hydroxypropyl cellulose, mixed with an appropriate amount of magnesium stearate, and then set using a rotary tableting machine. Tableting was performed with a hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
- Croscarmellose sodium (Ac-D To Sol, manufactured by Asahi Kasei Co., Ltd.) 50 g and light anhydrous caeic acid (Fad Solida 101, manufactured by Freund Sangyo Co., Ltd.) 50 g were kneaded in a mortar while adding an appropriate amount of water. . This was granulated with a 22 mesh sieve, dried at 60 ° C. for 18 hours, and then granulated with a 22 mesh sieve to obtain granules A.
- the tablet After mixing 20 parts by weight of aspirin with 80 parts by weight of the granulated particles obtained in Reference Example 2 and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, and the weight was 200 mg, diameter. 8mm, 9R tablets were obtained.
- 60 parts by weight of the granulated particles obtained in Reference Example 2 are mixed with 20 parts by weight of aspirin and 20 parts by weight of carmellose (NS-300, manufactured by Gotoku Pharmaceutical) and mixed with an appropriate amount of magnesium stearate, followed by rotary tableting. Tableting was performed using a machine with a set hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
- the tablet After mixing 70 parts by weight of the granulated particles obtained in Reference Example 2 with 30 parts by weight of aspirin and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
- the tablet After mixing 50 parts by weight of the granulated particles obtained in Reference Example 2 with 40 parts by weight of aspirin and 10 parts by weight of crospovidone, and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
- Mantol (Mannit p, manufactured by Towa Kasei Kogyo Co., Ltd.) 65 parts by weight, xylitol 5 parts by weight, crospovidone 8 parts by weight, crystalline cellulose 15 parts by weight, magnesium metasilicate aluminate 7 parts by weight in water And then spray-dried at an outlet temperature of 80 ° C using a spray dryer (L-8 type, manufactured by Okawahara Kako Co., Ltd.). Good fluidity! White spherical granulated particles Got.
- the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
- the tablet was tableted with a set hardness of 50 N using a rotary tableting machine to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
- the rotary tableting machine After mixing 50 parts by weight of acetaminophen with 50 parts by weight of the granulated particles obtained in Reference Example 3 and mixing an appropriate amount of magnesium stearate, the rotary tableting machine sets the hardness to 50 N, weight 200 mg, diameter. Force to try tableting as 8mm, 9R The upper limit pressure of the tableting machine exceeded 2400k gf, and the machine stopped, so it was impossible to obtain tablets.
- Tableting was performed using a tableting machine with a set hardness of 50 N, and tablets with a weight of 200 mg and a diameter of 8 mm ⁇ 9R were obtained.
- the content of the drug can be increased by adding at least one selected from the group consisting of excipient, disintegration aid and Z or binder force to the granulated particles in the present invention. It can be seen that good disintegration and good moldability can be obtained with higher hardness.
- spray dryer [L — 8 type, manufactured by Okawara Chemical Industries Co., Ltd.] was spray-dried at an outlet temperature of 80 ° C. to obtain white spherical granulated particles with good fluidity.
- the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
- the granulated particles obtained in Reference Example 4 are mixed with 64 parts by weight of acetaminophen 20 parts by weight and a crystal cell port. After mixing 16 parts by weight of the cellulose and an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
- the tablet After mixing 70 parts by weight of the granulated particles obtained in Reference Example 4 with 30 parts by weight of acetaminophen and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
- the set hardness is set to 50 N using a rotary tableting machine. As a result, tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
- the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
- 35 parts by weight of the granulated particles obtained in Reference Example 4 and 40 parts by weight of acetaminophen 25 parts by weight of the mixture was mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50 N to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
- the hardness is set to 50 N with a rotary tableting machine, weight 200 mg, diameter. Force to try tableting as 8mm and 9R The upper limit pressure of the tableting machine exceeded 2400kgf and the machine stopped, so it was impossible to obtain tablets.
- Tableting was performed with a tableting machine with a set hardness of 50 N, and tablets with a weight of 200 mg and a straightness of 8 mm 9 R were obtained.
- a spray dryer L 8 type, manufactured by Okawahara Chemical Co., Ltd.
- the granulated particles obtained in Reference Example 5 were mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
- the tablet After mixing 20 parts by weight of hydroxypropyl starch with 80 parts by weight of the granulated particles obtained in Reference Example 5 and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, and the weight is 200 mg. A tablet with a diameter of 8 mm and 9R was obtained.
- Tableting was performed using a rotary tableting machine with a set hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
- Crospovidone (50 g) and maltitol (manufactured by Towa Kasei Kogyo Co., Ltd.) (10 g) were kneaded in a mortar while preparing an appropriate amount of ethanol (99.5%). This was granulated with a 22 mesh sieve, dried at 60 ° C. for 18 hours, and then granulated with a 22 mesh sieve to obtain granules C.
- the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
- magnesium stearate was mixed with granule D, it was tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
- the tablet After mixing 1 part by weight of granule El with 89 parts by weight of the granulated particles obtained in Reference Example 5 and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, and the weight was 200 mg. Tablets with a diameter of 8 mm and 9R were obtained.
- Crospovidone (5 g), maltitol (20 g), magnesium metasilicate aluminate (5 g) and hydroxypropyl starch (70 g) were mixed with an appropriate amount of ethanol (99.5%) in a mortar. This was granulated with a 22 mesh sieve, dried at 60 ° C for 18 hours, and then granulated with a 22 mesh sieve to obtain granules F.
- Mantol (Mannit p, manufactured by Towa Kasei Kogyo Co., Ltd.) 63 parts by weight, 6 parts by weight of xylitol, 7 parts by weight of crospovidone, 19 parts by weight of crystalline cellulose, 5 parts by weight of magnesium metasilicate aluminate in water And then spray-dried at an outlet temperature of 90 ° C using a spray dryer (L-8 type, manufactured by Okawara Kako Co., Ltd.). Good fluidity! White spherical granulated particles Got.
- the tablet After mixing 70 parts by weight of the granulated particles obtained in Reference Example 6 with 30 parts by weight of ascorbic acid and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, and the weight is 200 mg. A tablet with a diameter of 8 mm and 9R was obtained.
- a tableting machine (compact high-speed rotary tableting machine VIRGO, Kikusui Manufacturing Co., Ltd.) To obtain a tablet with a tablet weight of 200 mg, a diameter of 8 mm and a flat corner.
- oral disintegrating tablets that were tableted by the external lubrication method obtained good moldability and disintegration, and were rapidly mixed with the lubricant and tableted in advance. It can be seen that the disintegration time is shorter than tablets, and the disintegration is superior.
- It can be provided as a tablet having sufficient hardness and good disintegration property in the oral cavity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
[PROBLEMS] To provide an orally rapidly disintegrating tablet which has sufficient level of hardness and molding property not to cause problems such as chipping or dusting during production or transport and also shows a good disintegrability in the oral cavity, while maintaining a high content of an active ingredient; and a process for producing an orally rapidly disintegrating tablet comprising shaping under compression using a conventional drug preparation facility. [MEANS FOR SOLVING PROBLEMS] The following ingredients (a) to (d) are mixed with one another: (a) a granulated particle comprising (i) an inorganic substance and (ii) a disintegrating agent dispersed homogenously in (iii) a composite particle made of at least two saccharides, which is optionally contains an active ingredient; (b) a lubricant; (c) at least one ingredient selected from an auxiliary disintegrating agent, an excipient and/or a binder; and (d) the active ingredient, and then the resulting mixture is shaped under compression by using a conventional drug preparation facility or by using a method in which a lubricant is previously coated onto the surfaces of a pestle and a mortar (external lubricating method). Thus, an orally rapidly disintegrating tablet can be prepared which has an excellent molding property, a good disintegrability and a satisfactory level of hardness even at a high active ingredient content.
Description
明 細 書 Specification
口腔内速崩壊性錠剤 Orally rapidly disintegrating tablets
技術分野 Technical field
[0001] 本発明は, 口腔内において速や力な崩壊性及び適度な硬度を有する口腔内速崩 壊性錠剤および生産性の高いその製造方法に関する。本発明の口腔内速崩壊性錠 剤は、医薬の分野において用いることができる。 [0001] The present invention relates to an intraoral rapidly disintegrating tablet having rapid and powerful disintegration property and appropriate hardness in the oral cavity, and a method for producing the same with high productivity. The intraoral rapidly disintegrating tablet of the present invention can be used in the field of medicine.
背景技術 Background art
[0002] 口腔内速崩壊錠は、口腔内で約 60秒以内の崩壊時間を有しつつ、錠剤製造時や 輸送中に錠剤の欠けや粉化がな 、程度の硬度を有する必要がある。硬度と崩壊時 間は反する要素であり、崩壊時間を速くした場合は硬度が低くなり、硬度を高くした 場合は崩壊時間が遅くなる。崩壊時間と硬度の問題を解決するため、口腔内速崩壊 性錠剤の製法としてはいくつかの方法が知られており、湿式打錠法、打錠加温法、 直接打錠法などがある。湿式打錠法、打錠加温法では、通常の圧縮成型による製剤 設備を用いることができず、加温装置や加湿装置、乾燥装置が必要であり、特別な 設備を必要とする。また、工程も通常の圧縮成型以外に、加湿、加温、乾燥などのェ 程を行うため、生産性にも問題があり、水溶性の活性成分には不向きである。 [0002] Intraoral rapidly disintegrating tablets have a disintegration time of about 60 seconds or less in the oral cavity, and need to have a certain degree of hardness so that the tablets are not chipped or pulverized during manufacture or transportation. Hardness and disintegration time are contradictory elements. If disintegration time is increased, the hardness decreases, and if the hardness is increased, the disintegration time decreases. In order to solve the problem of disintegration time and hardness, several methods are known for producing a rapidly disintegrating tablet in the oral cavity, including a wet tableting method, a tableting warming method, and a direct tableting method. In the wet tableting method and the tableting warming method, the usual preparation equipment for compression molding cannot be used, and a heating device, a humidifying device, and a drying device are required, and special equipment is required. In addition, the process involves processes such as humidification, warming, and drying in addition to normal compression molding, so there is a problem in productivity and it is not suitable for water-soluble active ingredients.
[0003] 一方、直接打錠法による口腔内速崩壊性錠剤の製法は、通常の製剤設備を用い ることができる。しかし、直接打錠法では、活性成分の含量を多くしながら、成形性、 適度な硬度ならびに崩壊性を併せて持たせるのは困難であり、これらを改善した製 法が知られている。例えば、活性成分と噴霧乾燥マンニトールとクロスポビドンおよび 医薬品に使用可能な賦形剤を乾式で混合した後、圧縮成型し、口腔内速崩壊性錠 剤を製する方法がある (特許文献 1参照)。 [0003] On the other hand, a method for producing an orally rapidly disintegrating tablet by the direct tableting method can use a normal preparation facility. However, in the direct tableting method, it is difficult to have both moldability, moderate hardness and disintegration while increasing the content of the active ingredient, and methods for improving these are known. For example, there is a method in which an active ingredient, spray-dried mannitol, crospovidone, and excipients that can be used for pharmaceuticals are dry mixed and then compression molded to produce an orally rapidly disintegrating tablet (see Patent Document 1). .
直打用に適した噴霧乾燥マン-トールとスーパー崩壊剤であるクロスポビドンを用い ることによって製した錠剤は、適度な成形性と崩壊性を有するが、口腔内速崩壊性錠 剤としての利用を考えた場合、得られる錠剤の口腔内崩壊時間と硬度とのノ ランスが 必ずしも充分なものではな ヽと 、う問題があった。 Tablets made by using spray-dried mannitol suitable for direct compression and crospovidone, a super disintegrant, have moderate moldability and disintegration, but can be used as an orally rapidly disintegrating tablet. However, there was a problem that the tolerance between the oral disintegration time and the hardness of the obtained tablets was not always sufficient.
[0004] 薬効成分、平均粒子径が 5 μ m〜90 μ m未満のマン-トール、平均粒子径が 90
μ πι〜500 /ζ mのマン-トール、崩壊剤および結晶セルロースを流動層造粒した後[0004] Medicinal properties, mantle with an average particle size of 5 μm to less than 90 μm, average particle size of 90 After fluidized bed granulation of μπι ~ 500 / ζ m of mantle, disintegrant and crystalline cellulose
、圧縮成型してなる口腔内速崩壊性錠剤を製する方法がある (特許文献 2参照)。こ の方法は、粒径の異なる 2種類の粒子を流動層造粒し、混合後圧縮成型するという、 複雑な工程を必要とした。また、これらの流動層造粒による粒子は原料由来の粒子 力 Sバインダーによって結合した非球形の顆粒状であり、粒子の各成分は粒子内に均 質に分散されていないため、口腔内速崩壊性錠剤に適した成形性'崩壊性を、必ず しも充分に満足させるものではな力つた。 There is a method of producing an intraorally rapidly disintegrating tablet formed by compression molding (see Patent Document 2). This method required a complicated process in which two types of particles with different particle sizes were fluidized, granulated, and then compression molded. In addition, the particles by fluidized bed granulation are non-spherical granules bound by the raw material-derived particle force S binder, and the components of the particles are not evenly dispersed in the particles, so the oral cavity rapidly disintegrates. However, it was not enough to satisfy the moldability and disintegration properties suitable for the active tablets.
[0005] また、本発明者らは以前、糖類の複合粒子に、崩壊剤、無機物を水に均質に分散 させたことを特徴とする口腔内速崩壊性錠用組成物を発明した (特許文献 3、 4参照) 。これらは、噴霧乾燥した造粒粒子を用いているため、圧縮成型機への計量性ゃ充 填性もよぐまた崩壊剤、無機物を均質に分散させた粒子であるため、良好な崩壊性 を示した。しかし、特許文献 3、 4の実施例にある活性成分と噴霧乾燥造粒物とを混 合圧縮した錠剤は、所望の崩壊性は得られるが硬度が充分ではなく(30— 40N)、 錠剤製造時や輸送中に錠剤の欠けや粉化と 、つた問題が生じる場合があった。また 、活性成分の含有率が高い場合、杵への貼り付きなどの打錠障害を起こす場合があ つた o [0005] In addition, the present inventors previously invented a composition for a rapidly disintegrating tablet in the oral cavity, wherein a disintegrant and an inorganic substance are uniformly dispersed in water in saccharide composite particles (Patent Document). (Refer to 3, 4). These are granulated particles that have been spray-dried, so that they have good meterability in a compression molding machine and are particles in which disintegrants and inorganic substances are homogeneously dispersed. Indicated. However, tablets obtained by mixing and compressing active ingredients and spray-dried granules in Examples of Patent Documents 3 and 4 can obtain the desired disintegration but have insufficient hardness (30-40N), and tablet manufacture Sometimes, problems such as chipping and powdering of tablets occurred during transportation. In addition, if the active ingredient content is high, tableting troubles such as sticking to the bag may occur.
特許文献 1:国際公開 00Z57857号パンフレット Patent document 1: International publication 00Z57857 pamphlet
特許文献 2:特開 2001— 58944号公報 Patent Document 2: Japanese Patent Laid-Open No. 2001-58944
特許文献 3:国際公開 2005Z037319号パンフレット Patent Document 3: International Publication 2005Z037319 Pamphlet
特許文献 4 :国際公開 2005Z037254号パンフレット Patent Document 4: International Publication 2005Z037254 Pamphlet
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0006] 本発明は、前述の従来技術における口腔内速崩壊性錠剤と比べて、活性成分の 含有率が高い場合に生じる問題がなぐ製造や輸送中に問題を生じない充分な硬度 と口腔内での良好な崩壊性を有する口腔内速崩壊性錠剤、及び生産性の高い口腔 内速崩壊性錠剤の製造方法を提供することを目的とする。 [0006] The present invention eliminates problems that occur when the content rate of the active ingredient is high compared to the above-described prior art oral disintegrating tablets, and has sufficient hardness that does not cause problems during production and transportation and the oral cavity. It is an object of the present invention to provide an intraoral rapidly disintegrating tablet having good disintegration property and a method for producing an intraoral rapidly disintegrating tablet having high productivity.
課題を解決するための手段 Means for solving the problem
[0007] 本発明者らは、上記の目的を達成するため鋭意研究した結果、(a) 2種以上の糖
類、無機物、崩壊剤を特定の割合で噴霧乾燥するか、又はさらに活性成分を加えて 噴霧乾燥することによって製した造粒粒子、(b)滑沢剤、(C)賦形剤、崩壊助剤及び Z又は結合剤から選ばれる少なくとも 1種以上、及び (d)活性成分を含有する錠剤が 、意外にも活性成分の含有率が高い場合に生じる問題がなぐまた、製造や輸送中 に問題を生じない充分な硬度と、良好な口腔内での崩壊性有すること、更には生産 性の高 、製造方法であることを発見するに至った。 [0007] As a result of intensive studies to achieve the above object, the present inventors have found that (a) two or more sugars Granulated particles made by spray drying a specific ratio of minerals, minerals and disintegrants, or by further adding active ingredients and spray drying, (b) lubricants, (C) excipients, disintegration aids At least one or more selected from agents and Z or binders, and (d) tablets containing the active ingredient are surprisingly free from problems that occur when the active ingredient content is high. It has been found that the production method has sufficient hardness that does not cause erosion, good disintegration property in the oral cavity, and high productivity.
[0008] 本発明における「口腔内速崩壊性錠剤」とは、口腔内で迅速に、例えば 40秒以内 で、より好ましくは 30秒以内で、さらに好ましくは 20秒以内で崩壊し得る錠剤を意味 する。ここでいう口腔内崩壊時間は、後述の口腔内速崩壊錠の条件や実施例の方法 で得られる時間である。口腔内での崩壊時間は、錠剤の大きさや、錠剤形状によって 異なるが、これも本願発明に含まれる。 [0008] The "orally-fast disintegrating tablet" in the present invention means a tablet that can disintegrate rapidly in the oral cavity, for example, within 40 seconds, more preferably within 30 seconds, and even more preferably within 20 seconds. To do. The oral disintegration time here is the time obtained by the conditions of the intraoral quick disintegrating tablet described later and the methods of the examples. The disintegration time in the oral cavity varies depending on the tablet size and tablet shape, and this is also included in the present invention.
発明の効果 The invention's effect
[0009] 本発明の口腔内速崩壊性錠剤用の組成物を用いて得られる錠剤は、従来の速崩 壊性錠剤に比べて、活性成分の含有が高ぐ製造や輸送中に問題を生じない充分 な硬度を有するにもかかわらず、良好な口腔内崩壊時間を有しているという特長を持 つ。したがって、該組成物に薬効成分を配合して得られる本発明の口腔内速崩壊性 錠剤は、口腔内で速や力な崩壊性が要求される医薬品に適している。 [0009] The tablet obtained by using the composition for rapidly disintegrating tablets in the oral cavity of the present invention has a higher active ingredient content than conventional quick disintegrating tablets, causing problems during production and transportation. It has the feature of having a good disintegration time in the oral cavity despite having a sufficient hardness. Therefore, the intraoral rapidly disintegrating tablet of the present invention obtained by blending a medicinal component with the composition is suitable for a pharmaceutical product that requires rapid or powerful disintegration in the oral cavity.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0010] 本発明の口腔内速崩壊性錠剤は、 (a) 2種以上の糖類の複合粒子中に、無機物及 び崩壊剤が均質に分散してなるか、及びさらに活性成分を含有する造粒粒子、 (b) 滑沢剤、(c)賦形剤、崩壊助剤及び Z又は結合剤カゝら選ばれる少なくとも 1種以上、 及び (d)活性成分からなる口腔内速崩壊性錠剤である。 [0010] The rapidly disintegrating tablet in the oral cavity of the present invention is (a) a structure in which an inorganic substance and a disintegrant are homogeneously dispersed in a composite particle of two or more saccharides, and further contains an active ingredient. (B) Lubricant, (c) At least one or more selected from excipients, disintegration aids and Z or binders, and (d) an orally rapidly disintegrating tablet comprising an active ingredient is there.
[0011] 以下、本発明に用いる造粒粒子について説明する。本発明に用いる造粒粒子は、 マン-トールとその他の糖類力もなる複合粒子中に、無機物、崩壊剤が均質に分散 してなるか、又はさらに活性成分を含有する造粒粒子である。この造粒粒子は、(ィ) 糖類、(口)崩壊剤、(ハ)無機物を水に分散させたあと噴霧乾燥するか、又は更に活 性成分を分散し噴霧乾燥することによって得られる。具体的には、国際公開 2005Z 037319号パンフレットまたは国際公開 2005Z037254号パンフレットに記載方法
よって製造される口腔内速崩壊性錠剤用の組成物である。これらの組成物は F— M ELT〔商標〕として富士化学工業 (株)によって、数種のタイプが製造販売されており 、いずれのタイプも用いることができる。 [0011] The granulated particles used in the present invention are described below. The granulated particle used in the present invention is a granulated particle in which an inorganic substance and a disintegrant are homogeneously dispersed in a composite particle having mannitol and other saccharide power, or further containing an active ingredient. These granulated particles can be obtained by spray-drying (i) saccharides, (mouth) disintegrants, and (c) inorganic substances in water and then spray-drying, or further dispersing active ingredients and spray-drying. Specifically, the method described in International Publication 2005Z 037319 or International Publication 2005Z037254 Therefore, it is a composition for intraoral rapidly disintegrating tablets manufactured. Several types of these compositions are manufactured and sold by Fuji Chemical Industry Co., Ltd. as F-M ELT [trademark], and any type can be used.
[0012] 本発明にお 、て、糖類とは糖および糖アルコールを 、う。本発明に用いる造粒粒 子に含まれる糖類は、マン-トールとマン-トール以外の糖類の組み合わせとなる。 マン-トール以外の糖類とは、例えば、キシリトール、ソルビトール、エリスリトール、マ ルチトール、乳糖、ショ糖、ブドウ糖、果糖、麦芽糖、トレハロース、パラチニットおよび パラチノースなど力も選ばれる少なくとも 1種以上である。マン-トールとマン-トール 以外の糖類との重量比は、マン-トール:マン-トール以外の糖類 = 98〜67: 2〜3 3、好ましくはマン-トール:マン-トール以外の糖類 = 97〜87: 3〜13、更に好まし くはマン-トール:マン-トール以外の糖類 = 96〜89: 4〜 11である。これらの糖類 のうち水に易溶性のものは平均粒子径がいずれのものを用いることができる。 In the present invention, the saccharide refers to sugar and sugar alcohol. The saccharide contained in the granulated particles used in the present invention is a combination of mannitol and saccharides other than mannitol. The saccharides other than mannitol are at least one or more selected from forces such as xylitol, sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, palatinit and palatinose. The weight ratio of mannitol to saccharides other than mannitol is: mannitol: saccharides other than mannitol = 98 to 67: 2-33, preferably mannitol: saccharides other than mannitol = 97 ~ 87: 3-13, more preferably man-tol: saccharides other than man-tol = 96-89: 4-11. Among these saccharides, those having an average particle size that are readily soluble in water can be used.
[0013] 本発明の造粒粒子に含まれる無機物としては、アルミニウム、マグネシウムおよび力 ルシゥムのいずれかを 1種以上含有する医薬上許容される無機酸ィ匕物が好ましぐ 例えばメタケイ酸アルミン酸マグネシウム、ケィ酸アルミン酸マグネシウム、リン酸水素 カルシウム、無水リン酸水素カルシウム、無水リン酸水素カルシウム造粒物、ハイド口 タルサイト、ケィ酸アルミニウム、リン酸カルシウム、炭酸カルシウム、ケィ酸カルシウム 、ケィ酸マグネシウム、酸化マグネシウム、水酸化マグネシウム、水酸化アルミナマグ ネシゥム、乾燥水酸ィ匕アルミニウムゲル、炭酸マグネシウムなど力 選ばれる少なくと も 1種以上である。より好ましくは、メタケイ酸アルミン酸マグネシウム、ケィ酸アルミン 酸マグネシウム、リン酸水素カルシウム、無水リン酸水素カルシウム、無水リン酸水素 カルシウム造粒物、ハイド口タルサイト、炭酸カルシウム、ケィ酸カルシウムおよび乾 燥水酸ィ匕アルミニウムゲル力 選ばれる少なくとも 1種以上であり、さらに好ましくは、 メタケイ酸アルミン酸マグネシウム、ハイド口タルサイト、無水リン酸水素カルシウムお よび炭酸カルシウム力も選ばれる少なくとも 1種以上である。これらの無機物の平均 粒子径としては 0. 1〜100 /ζ πιであり、好ましくは 1〜60 /ζ πιであり、更に好ましくは 1〜40 mである。所望の平均粒径を得るために、常法によって粉砕処理したものを 用!/、ることができる。
[0014] 本発明の造粒粒子に含まれる崩壊剤としては、クロスポビドン、クロスカルメロース ナトリウム、低置換度ヒドロキシプロピルセルロースおよび結晶セルロース力 選ばれ る少なくとも 1種以上が好ましぐこれらのいずれかを単独で用いてもよいが、複数の 混合物として用いることがより好ましい。中でもクロスポビドンと結晶セルロースを用い ることがさらに好ましい。クロスポビドンと結晶セルロースを用いる場合、クロスポビドン と結晶セルロースの重量比は、 5〜15 : 8〜22、好ましくは5〜14 : 10〜22、更に好 ましくは6〜13 : 12〜21でぁる。上記の崩壊剤は、本発明の組成物内での均質分散 性や口腔内でのざらつきを防ぐため、平均粒径が 0. 1〜: LOO /z mであるのが好ましく 、より好ましくは 1〜60 μ m、更に好ましくは 1〜40 μ mである。所望の平均粒径を得 るために、常法によって粉砕処理したものを用いることができる。 [0013] As the inorganic substance contained in the granulated particles of the present invention, a pharmaceutically acceptable inorganic acid containing at least one of aluminum, magnesium and strength aluminum is preferred. For example, aluminate metasilicate Magnesium, Magnesium aluminate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate granules, Hyde mouth talcite, aluminum silicate, calcium phosphate, calcium carbonate, calcium silicate, magnesium silicate, Magnesium oxide, magnesium hydroxide, alumina hydroxide, magnesium hydroxide, aluminum hydroxide gel, magnesium carbonate, etc. At least one selected. More preferably, magnesium aluminate metasilicate, magnesium aluminate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate granule, hydrated talcite, calcium carbonate, calcium silicate and dried At least one selected from hydroxyaluminum gel strength, more preferably at least one selected from magnesium aluminate metasilicate, hydrated talcite, anhydrous calcium hydrogen phosphate and calcium carbonate. The average particle diameter of these inorganic substances is 0.1 to 100 / ζ πι, preferably 1 to 60 / ζ πι, and more preferably 1 to 40 m. In order to obtain a desired average particle size, a product pulverized by a conventional method can be used! [0014] As the disintegrant contained in the granulated particles of the present invention, at least one selected from crospovidone, croscarmellose sodium, low-substituted hydroxypropylcellulose, and crystalline cellulose strength is preferred. May be used alone, but it is more preferable to use them as a mixture. Of these, crospovidone and crystalline cellulose are more preferably used. When using crospovidone and crystalline cellulose, the weight ratio of crospovidone and crystalline cellulose is 5-15: 8-22, preferably 5-14: 10-22, more preferably 6-13: 12-21. Ah. The above disintegrant preferably has an average particle size of 0.1 to: LOO / zm, more preferably 1 to 1 in order to prevent uniform dispersibility in the composition of the present invention and roughness in the oral cavity. The thickness is 60 μm, more preferably 1 to 40 μm. In order to obtain a desired average particle size, those obtained by pulverization by a conventional method can be used.
[0015] 本発明の造粒粒子の各成分の配合量は、造粒粒子全体の 100重量部に対して、 糖類 40〜90重量部、無機物 1〜30重量部、崩壊剤 5〜40重量部であり、好ましくは 造粒粒子全体の 100重量部に対して、糖類 50〜80重量部、無機物 2〜 15重量部、 崩壊剤 10〜36重量部である。更に好ましくは、造粒粒子全体の 100重量部に対し て、糖類 62〜78重量部、無機物 3〜8重量部、崩壊剤 18〜34重量部である。 [0015] The blending amount of each component of the granulated particle of the present invention is 40 to 90 parts by weight of saccharide, 1 to 30 parts by weight of an inorganic substance, and 5 to 40 parts by weight of a disintegrant with respect to 100 parts by weight of the entire granulated particle. Preferably, the amount is 50 to 80 parts by weight of saccharide, 2 to 15 parts by weight of an inorganic substance, and 10 to 36 parts by weight of a disintegrant with respect to 100 parts by weight of the whole granulated particles. More preferably, it is 62 to 78 parts by weight of saccharide, 3 to 8 parts by weight of an inorganic substance, and 18 to 34 parts by weight of a disintegrant with respect to 100 parts by weight of the whole granulated particles.
[0016] 本発明の造粒粒子は、マン-トールとマン-トール以外の糖類力もなる複合粒子中 に、崩壊剤および無機物を均質に分散した構造を有する。構成成分である糖類を複 合粒子にすることによって、口腔内速崩壊性錠剤用の組成物に適した高成形性、速 崩壊性及び錠剤硬度を与えることができる。更に、崩壊剤及び無機物を均質に分散 した構造を有することにより、口腔内での微少な水分をより多ぐそしてより速く錠剤内 部へ導入することができる。つまり、特定の無機物が持つ導水性の細孔が微少な水 分を錠剤内部へ呼び込み、共に分散している崩壊剤に有効に作用することで、口腔 内での良好な速崩壊性を与えることができる。 [0016] The granulated particles of the present invention have a structure in which a disintegrant and an inorganic substance are homogeneously dispersed in composite particles having man-tol and saccharide power other than man-tol. By making the saccharide, which is a component, into composite particles, high moldability, fast disintegration, and tablet hardness suitable for a composition for a rapidly disintegrating tablet in the oral cavity can be provided. Furthermore, by having a structure in which the disintegrant and the inorganic substance are homogeneously dispersed, a minute amount of moisture in the oral cavity can be introduced into the tablet more rapidly and more quickly. In other words, the water-conducting pores of a specific inorganic substance attract minute water into the tablet and effectively act on the disintegrant dispersed together, thereby giving good rapid disintegration in the oral cavity. Can do.
[0017] 本発明に用いる造粒粒子には、後述の活性成分、及び後述で示す崩壊性を損な わない範囲で医薬品に配合可能なその他の成分を配合することができ、活性成分の 配合量は、糖類、無機物と崩壊剤の合計 100重量部に対して、 0. 01〜80重量部で あり、好ましくは 0. 05〜70重量部であり、より好ましくは 0. 1〜60重量部である。後 述で詳細に述べるが活性成分は造粒粒子に含まず、造粒粒子に乾式で混合しても
よい。 [0017] The granulated particles used in the present invention can contain an active ingredient described later and other ingredients that can be added to a pharmaceutical within a range not impairing the disintegration property described later. The amount is 0.01 to 80 parts by weight, preferably 0.05 to 70 parts by weight, more preferably 0.1 to 60 parts by weight, based on 100 parts by weight of the saccharide, inorganic substance and disintegrant. It is. As will be described in detail later, the active ingredient is not contained in the granulated particles. Good.
[0018] 本発明に用いる造粒粒子は、所望の物性を得られる製造方法により製造することが でき、一般に用いられている方法、例えば噴霧乾燥法、流動層造粒乾燥法、攪拌造 粒法、湿式押出造粒法などの湿式造粒法で製造することができる。製造方法の容易 さ、および所望の物性を得やすい点から、噴霧乾燥法が好ましい。 [0018] The granulated particles used in the present invention can be produced by a production method capable of obtaining desired physical properties. Commonly used methods such as a spray drying method, a fluidized bed granulation drying method, and a stirring granulation method are used. It can be produced by a wet granulation method such as a wet extrusion granulation method. The spray drying method is preferred from the standpoint of ease of production and easy acquisition of desired physical properties.
[0019] 以下噴霧乾燥法を具体的に述べる。糖類、無機物及び崩壊剤を含む水性溶液又 は水性分散液を常法に従って噴霧乾燥することにより製造することができる。より具 体的には、糖類を予め水性溶媒に溶解又は分散させた後、崩壊剤及び無機物を均 質に分散させて得られた分散液を、噴霧乾燥することにより製造することができる。ま た、活性成分を含有するものは、上記成分の他に、活性成分を任意に添加してもよく 、また、崩壊性を損なわない範囲で後述に示す医薬品に配合可能なその他の成分 の 1種以上添加し均質分散させた分散液を、噴霧乾燥することにより製造することが できる。 [0019] The spray drying method will be specifically described below. It can be produced by spray-drying an aqueous solution or dispersion containing a saccharide, an inorganic substance and a disintegrant according to a conventional method. More specifically, after a saccharide is previously dissolved or dispersed in an aqueous solvent, a dispersion obtained by uniformly dispersing a disintegrant and an inorganic substance can be produced by spray drying. In addition to the above-mentioned components, those containing an active component may optionally contain an active component, and are one of the other components that can be added to the pharmaceuticals described below as long as they do not impair disintegration. It can be produced by spray-drying a dispersion in which more than seeds are added and homogeneously dispersed.
[0020] 上記溶媒としては、造粒粒子の特性に影響を及ぼさず、医薬的に許容される溶媒 であればよぐ例えば水、エタノール、メタノールなどが挙げられる。分散液は、公知 の方法により調製することができ、例えば、通常の撹拌、コロイドミル、高圧ホモジナイ ザ一、超音波照射などが挙げられるが、水性分散液中で粒子を高度に分散させ得る 方法であればよい。分散液中の濃度としては、分散液の粘土などによって噴霧乾燥 できる範囲であればよぐすなわち 5〜50重量%であり、好ましくは 10〜45重量%、 より好ましくは 25〜45重量%である。 [0020] Examples of the solvent include water, ethanol, methanol and the like as long as they are pharmaceutically acceptable solvents without affecting the characteristics of the granulated particles. The dispersion can be prepared by a known method, and examples thereof include ordinary stirring, colloid mill, high-pressure homogenizer, ultrasonic irradiation, etc., but a method capable of highly dispersing particles in an aqueous dispersion. If it is. The concentration in the dispersion is not particularly limited as long as it can be spray-dried with clay of the dispersion, that is, 5 to 50% by weight, preferably 10 to 45% by weight, more preferably 25 to 45% by weight. .
[0021] 噴霧乾燥の条件は特に限定されないが、噴霧乾燥機としては、円盤式またはノズ ル式の噴霧乾燥機を用いるのが好ましい。そして、噴霧乾燥の際の温度としては、入 口温度が約 120〜220°Cであり、出口温度は約 80〜130°Cが好ましい。噴霧乾燥 する際における水性分散液の固形物の濃度としては、噴霧乾燥できる範囲であれば よい。 [0021] The conditions for spray drying are not particularly limited, but it is preferable to use a disk-type or nozzle-type spray dryer as the spray dryer. As the temperature at the time of spray drying, the inlet temperature is preferably about 120 to 220 ° C, and the outlet temperature is preferably about 80 to 130 ° C. The concentration of the solid matter in the aqueous dispersion during spray drying may be in a range that allows spray drying.
[0022] このようにして得られる本発明に用いる造粒粒子の平均粒子径は、水性溶液または 水性分散液の濃度、噴霧乾燥方式、乾燥条件などにより適宜調製することができる 力 1〜500 μ m、好ましくは 5〜300 μ m、より好ましくは 10〜200 μ m、さらに好ま
しくは 30〜200 μ mであれば、 口腔内でのざらつきを防ぐことができて好まし!/、。 [0022] The average particle size of the granulated particles used in the present invention thus obtained can be appropriately adjusted depending on the concentration of the aqueous solution or dispersion, the spray drying method, the drying conditions, and the like. m, preferably 5 to 300 μm, more preferably 10 to 200 μm, even more preferred 30 to 200 μm is preferable because it can prevent roughening in the oral cavity! /.
[0023] 上記の造粒粒子の静的比容積は、好ましくは 1. 5〜4. Og/ml、より好ましくは 1. [0023] The static specific volume of the granulated particles is preferably 1.5 to 4. Og / ml, more preferably 1.
5〜3. 5gZml、さらに好ましくは 1. 5〜2. 5gZmlである。該造粒粒子は、このよう な静的比容積を有することにより、錠剤に成形する場合に臼に充填しやすいので製 剤化工程がスムーズに進み、また錠剤が均一に圧縮され、優れた打錠性を示すこと ができる。静的比容積は、標準の方法に従って測定することができる。また、良好な 流動性を有する粒子であるため、製剤化工程において優れた打錠性を示すことがで きる。 It is 5 to 3.5 gZml, more preferably 1.5 to 2.5 gZml. Since the granulated particles have such a static specific volume, they can be easily filled into a mortar when they are formed into tablets, so that the formulation process proceeds smoothly, the tablets are uniformly compressed, and excellent punching is achieved. Can show lockability. The static specific volume can be measured according to standard methods. In addition, since the particles have good fluidity, excellent tableting properties can be shown in the formulation process.
[0024] 本発明に用いる滑沢剤としては、例えば、アラビアゴム末、カカオ脂、カルナウバロ ゥ、カルメロースカルシウム、カルメロースナトリウム、カロぺプタイド、含水二酸化ケィ 素、乾燥水酸ィ匕アルミニウムゲル、グリセリン、ケィ酸マグネシウム、軽質無水ケィ酸、 軽質流動パラフィン、結晶セルロース、硬化油、合成ケィ酸アルミニウム、ゴマ油、コ ムギデンプン、サラシミツロウ、酸化マグネシウム、ジメチルポリシロキサン、酒石酸力 リウムナトリウム、ショ糖脂肪酸エステル、グリセリン脂肪酸エステル、シリコーン榭脂、 水酸化アルミニウムゲル、ステアリルアルコール、ステアリン酸、ステアリン酸アルミ- ゥム、ステアリン酸カルシウム、ステアリン酸ポリオキシル、ステアリン酸マグネシウム、 セタノール、ゼラチン、タルク、炭酸マグネシウム、沈降炭酸カルシウム、トウモロコシ デンプン、乳糖、ノ、ードフアット、白糖、バレイショテンプン、ヒドロキシプロピルセル口 ース、フマル酸、フマル酸ステアリルナトリウム、ポリエチレングリコール、ポリオキシェ チレンポリオキシプロピレングリコール、ポリソルベート、ミツロウ、メタケイ酸アルミン酸 マグネシウム、メチルセルロース、モクロウ、モノステアリン酸グリセリン、ラウリル硫酸 ナトリウム、硫酸カルシウム、硫酸マグネシウム、流動パラフィン、リン酸などがあげら れる。 [0024] Examples of the lubricant used in the present invention include gum arabic powder, cacao butter, carnauba roux, carmellose calcium, carmellose sodium, caropeptide, hydrous carbon dioxide, dry hydroxide-aluminum gel, Glycerin, magnesium silicate, light anhydrous carboxylic acid, light liquid paraffin, crystalline cellulose, hydrogenated oil, synthetic aluminum silicate, sesame oil, wheat starch, white beeswax, magnesium oxide, dimethylpolysiloxane, sodium tartrate, sucrose fatty acid ester , Glycerin fatty acid ester, silicone resin, aluminum hydroxide gel, stearyl alcohol, stearic acid, aluminum stearate, calcium stearate, polyoxyl stearate, magnesium stearate, cetanol, zera Chin, Talc, Magnesium carbonate, Precipitated calcium carbonate, Corn starch, Lactose, No, Dop fat, Sucrose, Potato tempo, Hydroxypropyl cellulose, Fumaric acid, Sodium stearyl fumarate, Polyethylene glycol, Polyoxyethylene Polyoxypropylene glycol , Polysorbate, beeswax, magnesium aluminate metasilicate, methyl cellulose, mole, glyceryl monostearate, sodium lauryl sulfate, calcium sulfate, magnesium sulfate, liquid paraffin, and phosphoric acid.
好ましくは、ステアリン酸、ステアリン酸マグネシウム、ステアリン酸カルシウム、ショ糖 脂肪酸エステル、ポリエチレングリコール、フマル酸ステアリルナトリウム、タルクである Preferably, stearic acid, magnesium stearate, calcium stearate, sucrose fatty acid ester, polyethylene glycol, sodium stearyl fumarate, talc
[0025] 本発明における賦形剤、崩壊助剤、結合剤とは、本発明の口腔内速崩壊性錠剤の 崩壊性及び成形性を高めることができる成分であり、一般に賦形剤、崩壊剤、結合剤
、崩壊助剤などに区分されるものが該当するが、ここではそれら用途に特に限定され るものではない。 [0025] The excipient, disintegration aid, and binder in the present invention are components that can improve the disintegration and moldability of the rapidly disintegrating tablet in the oral cavity of the present invention. , Binder However, it is not particularly limited to these applications.
本発明における賦形剤とは、例えば、アクリル酸デンプン、 Lーァスパラギン酸、アミ ノエチノレスノレホン酸、ァミノ酢酸、あめ(粉)、アラビアゴム、アラビアゴム末、ァノレギン 酸、アルギン酸ナトリウム、アルファ一化デンプン、イノシトール、ェチルセルロース、 エチレン酢酸ビュルコポリマー、エリスリトール、塩化ナトリウム、オリブ油、カオリン、力 カオ脂、カゼイン、果糖、軽石粒、カルメロース、カルメロースナトリウム、含水二酸ィ匕 ケィ素、乾燥酵母、乾燥水酸ィ匕アルミニウムゲル、乾燥硫酸ナトリウム、乾燥硫酸マグ ネシゥム、カンテン、カンテン末、キシリトール、クェン酸、クェン酸ナトリウム、クェン酸 ニナトリウム、グリセリン、グリセ口リン酸カルシウム、ダルコン酸ナトリウム、 L—ダルタミ ン、クレー、クレー粒、クロスカルメロースナトリウム、ケィ酸アルミニウム、合成ケィ酸ァ ルミ-ゥム ·ヒドロキシプロピルスターチ ·結晶セルロース、ケィ酸アルミン酸マグネシゥ ム、ケィ酸カルシウム、ケィ酸マグネシウム、軽質無水ケィ酸、軽質流動パラフィン、ケ ィヒ末、結晶セルロース、結晶セルロース 'カルメロースナトリウム、微粒子結晶セル口 ース、ゲンマイコウジ、合成ケィ酸アルミニウム、合成ヒドロタルサイト、ゴマ油、小麦粉 、コムギデンプン、小麦胚芽粉、コメコ(米粉)、コメデンプン、酢酸カリウム、酢酸カル シゥム、酢酸フタル酸セルロース、サフラワー油、サラシミツロウ、酸化亜鉛、酸化チタ ン、酸化マグネシウム、 j8—シクロデキストリン、ジヒドロキシアルミニウムアミノアセテ ート、 2, 6 ジ—tーブチルー 4 メチルフエノール、ジメチルポリシロキサン、酒石酸 、酒石酸水素カリウム、焼セッコゥ、ショ糖脂肪酸エステル、水酸ィ匕アルミナマグネシ ゥム、水酸ィ匕アルミニウムゲル、水酸ィ匕アルミニウム炭酸水素ナトリウム共沈物、水酸 ィ匕マグネシウム、スクヮラン、ステアリルアルコール、ステアリン酸、ステアリン酸カルシ ゥム、ステアリン酸ポリオキシル、ステアリン酸マグネシウム、精製ゼラチン、精製セラ ック、精製白糖、精製白糖球状顆粒、精製モンタンワックス、ゼイン、セスキォレイン 酸ソルビタン、セタノール、セッコゥ、セトステアリルアルコール、セラック、ゼラチン、ソ ルビタン脂肪酸エステル、 D—ソルビトール、第三リン酸カルシウム、ダイズ油、大豆 油不けん化物、大豆レシチン、脱脂粉乳、タルク、炭酸アンモ-ゥム、炭酸カルシウム 、炭酸マグネシウム、中性無水硫酸ナトリウム、低置換度ヒドロキシプロピルセルロー
ス、デキストラン、デキストリン、天然ケィ酸アルミニウム、トウモロコシシロップ、トウモロ コシデンプン、トレハロース、トラガント、二酸化ケイ素、乳酸カルシウム、乳糖、ハイド 口タルサイト、麦芽糖、白色セラック、白色ワセリン、ノ、クド、白糖、白糖デンプン球状 顆粒、ハダカムギ緑葉エキス末、ハダカムギ緑葉青汁乾燥粉末、ハチミツ、パラチ- ット、パラチノース、パラフィン、バレイショデンプン、半消化体デンプン、人血清アル ブミン、ヒドロキシプロピルスターチ、ヒドロキシプロピルセルロース、フィチン酸、ブドウ 糖、ブドウ糖水和物、部分アルファ一化デンプン、プルラン、プロピレングリコール、 粉末還元麦芽糖水ァメ、粉末セルロース、ぺクチン、ベントナイト、ポリアクリル酸ナト リウム、ポリエチレングリコール、ポリオキシエチレンアルキルエーテル、ポリオキシェ チレン硬化ヒマシ油類、ポリオキシエチレン 'ポリオキシプロピレン'グリコール、ポリス チレンスルホン酸ナトリウム、ポリソルベート、ポリビニルァセタールジェチルアミノアセ テート、ポリビュルピロリドン、マルチトール、マルトース、 D—マン-トール、水ァメ、ミ リスチン酸イソプロピル、無水乳糖、無水リン酸水素カルシウム、無水リン酸水素カル シゥム造粒物、メタケイ酸アルミン酸マグネシウム、メチルセルロース、綿実粉、綿実 油、モクロウ、モノステアリン酸アルミニウム、モノステアリン酸グリセリン、モノステアリ ン酸ソルビタン、無水ケィ酸、薬用炭、ラッカセィ油、硫酸アルミニウム、硫酸カルシゥ ム、粒状石灰石、粒状トウモロコシデンプン、流動パラフィン、 dl—リンゴ酸、リン酸一 水素カルシウム、リン酸水素カルシウム、リン酸水素カリウム、リン酸水素ナトリウムな どの 1種以上であり、これらのいずれかを単独で用いてもよいが、 2種以上を配合する ことができる。 The excipient in the present invention includes, for example, starch acrylate, L-aspartic acid, aminoethinolesnorephonic acid, aminoacetic acid, candy (powder), gum arabic, gum arabic powder, anoregic acid, sodium alginate, alpha-1 Modified starch, inositol, ethyl cellulose, ethylene acetate butyl copolymer, erythritol, sodium chloride, olive oil, kaolin, strength kaolin, casein, fructose, pumice grains, carmellose, carmellose sodium, hydrous diacid Yeast, dry hydroxyaluminum gel, dry sodium sulfate, dry magnesium sulfate, agar, agar powder, xylitol, citrate, sodium citrate, disodium citrate, glycerin, calcium glycephosphate, sodium dalconate, L- Dartami , Clay, clay grains, croscarmellose sodium, aluminum silicate, synthetic aluminum carbonate, hydroxypropyl starch, crystalline cellulose, magnesium aluminate, calcium silicate, magnesium silicate, light anhydrous key acid , Light liquid paraffin, coffee powder, crystalline cellulose, crystalline cellulose 'carmellose sodium, fine crystalline cell mouth, pearl millet, synthetic aluminum silicate, synthetic hydrotalcite, sesame oil, wheat flour, wheat starch, wheat germ powder , Rice (rice flour), rice starch, potassium acetate, calcium acetate, cellulose acetate phthalate, safflower oil, honey beeswax, zinc oxide, titanium oxide, magnesium oxide, j8-cyclodextrin, dihydroxyaluminum aminoacetate, 2, 6 —T-Butyl-4 Methylphenol, dimethylpolysiloxane, tartaric acid, potassium hydrogen tartrate, calcined gypsum, sucrose fatty acid ester, hydroxyalumina magnesium, hydroxyaluminum gel, hydroxyaluminum sodium bicarbonate Precipitate, magnesium hydroxide, squalane, stearyl alcohol, stearic acid, calcium stearate, polyoxyl stearate, magnesium stearate, purified gelatin, purified saccharose, purified white sugar, purified white sugar spherical granules, purified montan wax Zein, sesquioleate sorbitan, cetanol, gypsum, cetostearyl alcohol, shellac, gelatin, sorbitan fatty acid ester, D-sorbitol, tricalcium phosphate, soybean oil, soybean oil unsaponifiable matter, soybean lecithin, defatted Milk, talc, carbonate ammonium - © beam, calcium carbonate, magnesium carbonate, sodium neutral anhydrous sulfate, low-substituted hydroxypropyl cell row , Dextran, dextrin, natural aluminum silicate, corn syrup, corn starch, trehalose, tragacanth, silicon dioxide, calcium lactate, lactose, hyde mouth talcite, maltose, white shellac, white petrolatum, white, kuddo, white sugar, white sugar Starch spherical granules, green leaf extract, green leaf green juice powder, honey, palatin, palatinose, paraffin, potato starch, semi-digested starch, human serum albumin, hydroxypropyl starch, hydroxypropylcellulose, phytic acid , Glucose, glucose hydrate, partially alpha starch, pullulan, propylene glycol, powdered maltose starch, powdered cellulose, pectin, bentonite, sodium polyacrylate, polyester Polyethylene glycol, polyoxyethylene alkyl ether, polyoxyethylene hydrogenated castor oil, polyoxyethylene 'polyoxypropylene' glycol, sodium polystyrene sulfonate, polysorbate, polyvinylacetal jetylaminoacetate, polybutyropyrrolidone, maltitol, Maltose, D-manntol, starch, isopropyl myristate, anhydrous lactose, anhydrous calcium hydrogen phosphate, anhydrous calcium phosphate calcium granulated product, magnesium aluminate metasilicate, methylcellulose, cottonseed powder, cottonseed Oil, molasses, aluminum monostearate, glyceryl monostearate, sorbitan monostearate, anhydrous caustic acid, medicinal charcoal, peanut oil, aluminum sulfate, calcium sulfate, granular limestone, granular corn One or more of starch, liquid paraffin, dl-malic acid, calcium monohydrogen phosphate, calcium hydrogen phosphate, potassium hydrogen phosphate, sodium hydrogen phosphate, and any of these may be used alone Two or more types can be blended.
好ましくは、結晶セルロース、粉末セルロース、クロスカルメロースナトリウム、メタケイ 酸アルミン酸マグネシウム、ケィ酸アルミン酸マグネシウム、リン酸水素カルシウム、無 水リン酸水素カルシウム、無水リン酸水素カルシウム造粒物、ハイド口タルサイト、ベ ントナイト、ケィ酸アルミニウム、リン酸カルシウム、炭酸カルシウム、ケィ酸カルシウム 、ケィ酸マグネシウム、酸化マグネシウム、水酸化マグネシウム、水酸化アルミナマグ ネシゥム、乾燥水酸ィ匕アルミニウムゲル、炭酸マグネシウム、コムギデンプン、コメデ ンプン(ライススターチ)、トウモロコシデンプン(コーンスターチ)、バレイショデンプン ゝ部分アルファ一化デンプン、ヒドロキシプロピルスターチ、マン-トール、キシリトー
ル、ソルビトール、エリスリトール、マルチトール、乳糖、白糖、ブドウ糖、果糖、麦芽糖 、トレハロース、パラチニット、パラチノース、カンテン、セラック、トラガントである。 より好ましくは、結晶セルロース、クロスカルメロースナトリウム、メタケイ酸アルミン酸マ グネシゥム、ケィ酸アルミン酸マグネシウム、リン酸水素カルシウム、無水リン酸水素力 ルシゥム、無水リン酸水素カルシウム造粒物、ケィ酸カルシウム、ケィ酸アルミニウム、 無水ケィ酸、ハイド口タルサイトである。 Preferably, crystalline cellulose, powdered cellulose, croscarmellose sodium, magnesium aluminate metasilicate, magnesium aluminate silicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate granule, hyde mouth tar Sight, bentonite, aluminum silicate, calcium phosphate, calcium carbonate, calcium silicate, magnesium silicate, magnesium oxide, magnesium hydroxide, magnesium hydroxide magnesium, dried hydroxyaluminum gel, magnesium carbonate, wheat starch, rice Open rice (rice starch), corn starch (corn starch), potato starch ゝ Partial alpha-unified starch, hydroxypropyl starch, man-toll, xylitol And sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, palatinit, palatinose, agar, shellac and tragacanth. More preferably, crystalline cellulose, croscarmellose sodium, magnesium metasilicate aluminate, magnesium aluminate, calcium hydrogen phosphate, anhydrous hydrogen phosphate power, anhydrous calcium hydrogen phosphate granules, calcium silicate, These are aluminum silicate, anhydrous hydrate, and hydrated talcite.
本発明における崩壊助剤とは、例えば、アジピン酸、アルギン酸、アルギン酸ナトリ ゥム、アルファ一化デンプン、エリスリトール、果糖、カルボキシメチルスターチナトリウ ム、カルメロース、カルメロースカルシウム、カルメロースナトリウム、含水二酸化ケイ素 、カンテン、キシリトール、グァーガム、クェン酸カルシウム、クロスカルメロースナトリウ ム、クロスポビドン、合成ケィ酸アルミニウム、ケィ酸アルミン酸マグネシウム、低置換 度ヒドロキシプロピノレセルロース、結晶セルロース、結晶セルロース '力ノレメロースナト リウム、コムギデンプン、コメデンプン、酢酸フタル酸セルロース、ジォクチルソジゥム スルホサクシネート、ショ糖脂肪酸エステル、水酸ィ匕アルミナマグネシウム、ステアリン 酸カルシウム、ステアリン酸ポリオキシル、セスキォレイン酸ソルビタン、ゼラチン、セラ ック、ソルビトール、ソルビタン脂肪酸エステル、タルク、炭酸水素ナトリウム、炭酸マ グネシゥム、沈降炭酸カルシウム、デキストリン、デヒドロ酢酸ナトリウム、トウモロコシ デンプン、トラガント、トレハロース、乳糖、麦芽糖、白糖、ハイド口タルサイト、ハチミツ 、パラチニット、パラチノース、バレイショデンプン、ヒドロキシェチルメチルセルロース 、ヒドロキシプロピルスターチ、ヒドロキシプロピルセルロース、ブドウ糖、ベントナイト、 部分アルファ一化デンプン、フマル酸一ナトリウム、ポリエチレンダルコール、ポリオキ シエチレン硬化ヒマシ油、ポリオキシエチレン 'ポリオキシプロピレン 'グリコール、ポリ ソルベート、ポリビュルァセタールジェチルァミノアセテート、ポリビュルピロリドン、マ ルチトール、 D—マン-トール、無水クェン酸、無水ケィ酸、メタケイ酸アルミン酸マグ ネシゥム、メチルセルロース、モノステアリン酸グリセリン、ラウリル硫酸ナトリウムなどの 1種以上であり、これらのいずれかを単独で用いてもよいが、 2種以上を配合すること ができる。 Examples of the disintegration aid in the present invention include adipic acid, alginic acid, sodium alginate, alpha-monoized starch, erythritol, fructose, carboxymethyl starch sodium, carmellose, carmellose calcium, carmellose sodium, hydrous silicon dioxide, Kantene, Xylitol, Guar gum, Calcium citrate, Croscarmellose sodium, Crospovidone, Synthetic aluminum silicate, Magnesium aluminate, Low-substituted hydroxypropinolecellulose, Crystalline cellulose, Crystalline cellulose 'Power normelose sodium, Wheat starch , Rice starch, cellulose acetate phthalate, dioctyl sodium sulfosuccinate, sucrose fatty acid ester, hydroxyalumina magnesium, calcium stearate , Polyoxyl stearate, sorbitan sesquioleate, gelatin, cerac, sorbitol, sorbitan fatty acid ester, talc, sodium bicarbonate, magnesium carbonate, precipitated calcium carbonate, dextrin, sodium dehydroacetate, corn starch, tragacanth, trehalose, lactose, Maltose, sucrose, hydrated talcite, honey, palatinit, palatinose, potato starch, hydroxyethyl methylcellulose, hydroxypropyl starch, hydroxypropylcellulose, glucose, bentonite, partially alpha-monoized starch, monosodium fumarate, polyethylene dalcol, Polyoxyethylene hydrogenated castor oil, polyoxyethylene 'polyoxypropylene' glycol, polysorbate, polybiethylene 1 type of substances such as rucetal jetylaminoacetate, polybutyrrolidone, maltitol, D-manntol, anhydrous citrate, anhydrous silicate, magnesium metasilicate aluminate, methylcellulose, glyceryl monostearate, sodium lauryl sulfate Any one of these may be used alone, but two or more of them can be blended.
好ましくは、低置換度ヒドロキシプロピルセルロース、結晶セルロース、カルメロース、
クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、クロスポビドン、メ タケイ酸アルミン酸マグネシウム、ケィ酸アルミン酸マグネシウム、合成ケィ酸アルミ- ゥム、沈降炭酸カルシウム、水酸ィ匕アルミナマグネシウム、炭酸マグネシウム、コムギ デンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、部分アルファ一 ィ匕デンプン、ヒドロキシプロピルスターチ、マン-トール、キシリトール、ソルビトール、 エリスリトール、マルチトール、乳糖、白糖、ブドウ糖、果糖、麦芽糖、トレハロース、パ ラチニット、パラチノース、カンテン、セラック、トラガントである。 Preferably, low substituted hydroxypropyl cellulose, crystalline cellulose, carmellose, Croscarmellose sodium, sodium carboxymethyl starch, crospovidone, magnesium aluminate metasilicate, magnesium aluminate, synthetic aluminum carbonate, precipitated calcium carbonate, hydroxyalumina magnesium carbonate, magnesium carbonate, wheat starch , Rice starch, corn starch, potato starch, partially alpha starch, hydroxypropyl starch, mannitol, xylitol, sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, paranit, palatinose , Kanten, Shellac, Tragant.
より好ましくは、低置換度ヒドロキシプロピルセルロース、結晶セルロース、カルメロ一 ス、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、コメデンプン、 トウモロコシデンプン、クロスポビドン、メタケイ酸アルミン酸マグネシウム、ケィ酸アル ミン酸マグネシウム、合成ケィ酸アルミニウムである。 More preferably, low-substituted hydroxypropyl cellulose, crystalline cellulose, carmellose, croscarmellose sodium, sodium carboxymethyl starch, rice starch, corn starch, crospovidone, magnesium aluminate metasilicate, magnesium alginate, Synthetic aluminum silicate.
本発明における結合剤とは、例えば、アクリル酸ェチル 'メタクリル酸メチル共重合 体乳濁液、ァセチルグリセリン脂肪酸エステル、アミノアルキルメタクリレートコポリマ 一 E、アミノアルキルメタクリレートコポリマー RS、アミノエチルスルホン酸、あめ(粉)、 アラビアゴム、アラビアゴム末、アルギン酸ナトリウム、アルギン酸プロピレングリコール エステル、アルファ一化デンプン、エステルガム H、ェチルセルロース、ォゥバタ末、 加水分解ゼラチン末、カゼインナトリウム、果糖、カラメル、カラャガム末、カルボキシ ビュルポリマー、カルボキシメチルェチルセルロース、カルボキシメチルスターチナト リウム、カルメロース、カルメロースナトリウム、含水二酸化ケイ素、カンテン、寒梅粉、 キサンタンガム、牛脂硬化油、グァーガム、グリセリン、合成ケィ酸アルミニウム、軽質 無水ケィ酸、軽質無水ケィ酸含有ヒドロキシプロピルセルロース、結晶セルロース、硬 化油、コポリビドン、ゴマ油、小麦粉、コムギデンプン、コメコ(米粉)、コメデンプン、酢 酸ビュル榭脂、酢酸フタル酸セルロース、サラシミツロウ、酸化デンプン、ジォクチル ソジゥムスルホサクシネート、ジヒドロキシアルミニウムァミノアセテート、酒石酸ナトリウ ムカリウム、ショ糖脂肪酸エステル、ステアリルアルコール、ステアリン酸、ステアリン酸 カルシウム、ステアリン酸ポリオキシル、セスキォレイン酸ソルビタン、セタノール、ゼラ チン、セラック、ソルビタン脂肪酸エステル、 D—ソルビトール、大豆レシチン、炭酸力 ルシゥム、単シロップ、デキストリン、デンプン(溶性)、トウモロコシデンプン、トラガント
、パラフィン、バレイショデンプン、ヒドロキシェチルセルロース、ヒドロキシェチルメチ ノレセノレロース、ヒドロキシプロピノレスターチ、ヒドロキシプロピノレセノレロース、ヒドロキシ プロピルメチルセルロース、ヒドロキシプロピルメチルセルロースアセテートサクシネー ト、ヒドロキシプロピノレメチノレセルロースフタレート、ピぺ口-ルブトキシド、ブチルフタリ ルブナルグリコレート、ブドウ糖、部分アルファ一化デンプン、フマル酸、プルラン、プ ロピレンダリコール、ぺクチン、ポリアクリル酸ナトリウム、ポリアクリル酸部分中和物、 ポリエチレングリコール、ポリオキシエチレン.ポリオキシプロピレン.グリコール、ポリソ ルベート、ポリビュルァセタールジェチルァミノアセテート、ポリビュルアルコール(完 全けん化物)、ポリビニルアルコール(部分けん化物)、ポリビニルピロリドン、ポリブテ ン、ポリリン酸ナトリウム、 D—マン-トール、水ァメ、軽質無水ケィ酸、メタケイ酸アルミ ン酸マグネシウムなどの 1種以上であり、これらのいずれかを単独で用いてもよいが、 2種以上を配合することができる。 The binder in the present invention includes, for example, ethyl acrylate 'methyl methacrylate copolymer emulsion, acetyl glycerin fatty acid ester, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate copolymer RS, aminoethyl sulfonic acid, candy ( Flour), gum arabic, gum arabic powder, sodium alginate, propylene glycol alginate, alpha starch starch, ester gum H, ethyl cellulose, ovata powder, hydrolyzed gelatin powder, sodium caseinate, fructose, caramel, carragham powder, carboxy Bull polymer, carboxymethylethyl cellulose, carboxymethyl starch sodium, carmellose, carmellose sodium, hydrous silicon dioxide, agar, ume powder, xanthan gum, beef tallow Oil, Guar gum, Glycerin, Synthetic aluminum silicate, Light anhydrous carboxylic acid, Hydroxypropylcellulose containing light anhydrous carboxylic acid, Crystalline cellulose, Hardened oil, Copolyvidone, Sesame oil, Wheat flour, Wheat starch, Rice coconut (rice flour), Rice starch, Vinegar Acid burr, cellulose acetate phthalate, white beeswax, oxidized starch, dioctyl sodium sulfosuccinate, dihydroxyaluminum aminoacetate, potassium sodium tartrate, sucrose fatty acid ester, stearyl alcohol, stearic acid, calcium stearate, stearin Acid polyoxyl, sorbitan sesquioleate, cetanol, gelatin, shellac, sorbitan fatty acid ester, D-sorbitol, soybean lecithin, carbonated lucyme, simple syrup, dextrin, Npun (soluble), corn starch, tragacanth , Paraffin, potato starch, hydroxyethyl cellulose, hydroxyethyl methylenoresellose, hydroxypropinorestarch, hydroxypropenoresenorelose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate succinate, hydroxypropinoremethinolecellulose phthalate, pipette Mouth-rubbutoxide, butylphthalyl glycolate, glucose, partially alpha-monoized starch, fumaric acid, pullulan, polypropylene alcohol, pectin, sodium polyacrylate, partially neutralized polyacrylic acid, polyethylene glycol, polyoxyethylene . Polyoxypropylene. Glycol, Polysorbate, Polybulacetal Jetylaminoacetate, Polybulu alcohol ( Completely saponified product), polyvinyl alcohol (partially saponified product), polyvinyl pyrrolidone, polybutene, sodium polyphosphate, D-manntol, starch, light anhydrous caustic acid, magnesium metasilicate aluminate, etc. Any of these may be used alone, but two or more of them may be blended.
[0029] 本発明に用いる活性成分としては、特に限定されず、末梢神経用剤、解熱鎮痛消 炎剤、催眠鎮静剤、精神神経用剤などの中枢神経用薬剤;骨格筋弛緩剤、自律神 経剤などの末梢神経用薬剤;強心剤、不整脈用剤、利尿剤、血管拡張剤などの循環 器用薬剤;気管支拡張剤、鎮咳剤などの呼吸器官用薬剤;消化剤、整腸剤、制酸剤 などの消化管用薬剤;ホルモン剤、抗ヒスタミン剤、ビタミン剤などの代謝性薬剤;抗 潰瘍剤;抗生物質;化学療法剤;生薬エキス剤;微生物類などが挙げられる。 [0029] The active ingredient used in the present invention is not particularly limited, and is a central nerve agent such as a peripheral nerve agent, an antipyretic analgesic / antiinflammatory agent, a hypnotic sedative, or a neuropsychiatric agent; a skeletal muscle relaxant, an autonomic god Peripheral nerve drugs such as transdermal drugs; Cardiovascular drugs such as cardiotonic drugs, arrhythmia drugs, diuretics, vasodilators; respiratory drugs such as bronchodilators and antitussives; Digestives such as digestives, intestinal drugs, and antacids Tube drugs; metabolic drugs such as hormones, antihistamines and vitamins; anti-ulcer agents; antibiotics; chemotherapeutic agents; herbal extracts;
[0030] 活性成分は、苦味の隠蔽や放出制御を目的として、コーティングなどの公知の方法 で処理したものを用いることができる。また消化管内での放出を行わせるために公知 の方法で放出制御したものであってもよい。活性成分は、口腔内でのざらつき感ゃ 服用感を高めるために粉砕したものを配合することができ、平均粒径 0. 1〜: LOO m が好ましい。 [0030] As the active ingredient, those processed by a known method such as coating can be used for the purpose of concealing bitterness and controlling release. Moreover, in order to release in the digestive tract, the release may be controlled by a known method. If the active ingredient is rough in the oral cavity, it can be blended in order to enhance the feeling of taking, and an average particle size of 0.1 to LOO m is preferred.
活性成分は、上記造粒粒子内外のいずれ力もしくは両方に含まれていれば良ぐ 造粒粒子中に含まれない場合には、(a)造粒粒子、(b)滑沢剤、及び (c)賦形剤、崩 壊助剤及び Z又は結合剤から選ばれる少なくとも 1種以上と混合する時点で配合す ればよい。 The active ingredient should be contained in either or both of the above and outside of the granulated particles. If not included in the granulated particles, (a) the granulated particles, (b) the lubricant, and ( c) What is necessary is just to mix | blend at the time of mixing with at least 1 or more types chosen from an excipient | filler, a disintegration aid, and Z or binder.
[0031] 本発明の口腔内速崩壊錠は、錠剤全体 100重量部に対して、(a)造粒粒子 1〜98
重量部、(b)滑沢剤 0. 01〜5重量部、(c)賦形剤、崩壊助剤及び Z又は結合剤から 選ばれる少なくとも 1種以上 1〜98重量部、(d)活性成分 0. 01〜60重量部からなる 。より好ましくは、錠剤全体 100重量部に対して、(a)造粒粒子 5〜90重量部、(b)滑 沢剤 0. 1〜3重量部、(c)賦形剤、崩壊助剤及び Z又は結合剤から選ばれる少なく とも 1種以上 5〜90重量部、(d)活性成分 0. 1〜50重量部力もなる。 [0031] The rapidly disintegrating tablet in the oral cavity of the present invention comprises (a) granulated particles 1 to 98 with respect to 100 parts by weight of the whole tablet. Parts by weight, (b) lubricant 0.01 to 5 parts by weight, (c) at least one selected from excipients, disintegration aids and Z or binders 1 to 98 parts by weight, (d) active ingredient 0. Consists of 01-60 parts by weight. More preferably, for 100 parts by weight of the whole tablet, (a) 5 to 90 parts by weight of granulated particles, (b) 0.1 to 3 parts by weight of lubricant, (c) excipient, disintegration aid and At least one selected from Z or a binder is 5 to 90 parts by weight, and (d) the active ingredient is 0.1 to 50 parts by weight.
[0032] 本発明の口腔内速崩壊性錠剤には崩壊性を損なわない範囲で医薬品に配合可 能なその他の成分を配合することができる。本発明の口腔内速崩壊性錠剤に配合す ることができる崩壊性を損なわな ヽ成分としては、界面活性剤 (例えばポリオキシェチ レン硬化ひまし油、ポリオキシエチレンポリオキシプロピレングリコール、ソルビタン脂 肪酸エステル、ポリソルベート、グリセリン脂肪酸エステル、ラウリル硫酸ナトリウム等)[0032] The intraoral rapidly disintegrating tablet of the present invention can be blended with other components that can be blended with pharmaceuticals as long as the disintegration property is not impaired. Surfactants that do not impair disintegration that can be incorporated into the rapidly disintegrating tablet of the present invention include surfactants (for example, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan fatty acid ester, Polysorbate, glycerin fatty acid ester, sodium lauryl sulfate, etc.)
、酸味料 (例えばクェン酸、酒石酸、リンゴ酸、ァスコルビン酸など)、発泡剤(例えば 炭酸水素ナトリウム、炭酸ナトリウムなど)、甘味剤 (サッカリンナトリウム、グリチルリチ ン酸ニカリウム、アスパルテーム、ステビア、ソーマチンなど)、香料(例えばレモン油 、オレンジ油、メントールなど)、着色剤(例えば食用赤色 2号、食用青色 2号、食用黄 色 5号、食用レーキ色素、三二酸ィ匕鉄など)、安定化剤(例えばェデト酸ナトリウム、ト コフエロール、シクロデキストリンなど)、矯味剤、着香剤などが挙げられる。 , Acidulants (eg, citrate, tartaric acid, malic acid, ascorbic acid), foaming agents (eg, sodium bicarbonate, sodium carbonate), sweeteners (sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia, thaumatin), flavoring (E.g. lemon oil, orange oil, menthol, etc.), colorants (e.g. edible red No. 2, edible blue No. 2, edible yellow No. 5, edible lake dye, ferric trioxide, etc.), stabilizers (e.g. Edetate sodium, tocopherol, cyclodextrin, etc.), flavoring agents, and flavoring agents.
[0033] 本発明の口腔内速崩壊性錠剤は、(a)造粒粒子、(b)滑沢剤、(c)賦形剤、崩壊助 剤及び Z又は結合剤から選ばれる少なくとも 1種以上、及び (d)活性成分、その他の 医薬品に配合可能な成分を混合したのち、圧縮成型することによって製造することが できる。圧縮成型は、直接打錠法によるのが好ましぐその際の打錠圧は、錠剤の大 きさにより異なり、製剤可能な打錠圧の範囲内で選ぶことができる。 [0033] The rapidly disintegrating tablet in the oral cavity of the present invention is at least one or more selected from (a) granulated particles, (b) a lubricant, (c) an excipient, a disintegration aid and Z or a binder. And (d) It can be produced by mixing the active ingredient and other ingredients that can be blended with pharmaceuticals, followed by compression molding. The compression molding is preferably performed by the direct tableting method. The tableting pressure at that time depends on the size of the tablet and can be selected within the range of tableting pressure that can be formulated.
[0034] その他の製法としては、(a)造粒粒子、(b)滑沢剤、(c)賦形剤、崩壊助剤及び Z 又は結合剤カゝら選ばれる少なくとも 1種以上、及び (d)活性成分を湿式造粒したのち 、圧縮成型してもよい。湿式造粒の方法としては、噴霧乾燥法、流動層造粒乾燥法、 攪拌造粒法、湿式押出造粒法があげられる。また、圧縮成型後、常法に従って加温 や加湿などのエージングを行って、所望の硬度'崩壊性を付与することができる。 [0034] The other production methods include (a) granulated particles, (b) lubricant, (c) excipient, disintegration aid and at least one selected from Z or binder, and d) The active ingredient may be subjected to compression molding after wet granulation. Examples of wet granulation methods include spray drying, fluidized bed granulation drying, stirring granulation, and wet extrusion granulation. In addition, after compression molding, aging such as heating and humidification can be performed according to a conventional method to impart desired hardness' disintegration property.
[0035] 本発明における口腔内速崩壊性錠剤の製造においては、上述のように滑沢剤を他 の成分と一緒にほかの配合成分と混合した後に圧縮成型してもよいが、滑沢剤を他
の成分と混合することなぐ圧縮成型機の杵の表面および臼の壁面にあらかじめ塗 布し、圧縮成型する方法 (外部滑沢法)で製造することが可能で、所望の硬度や崩壊 性を付与することができる。滑沢剤を杵臼に塗布する方法は、従来の公知の方法や 機械で行うことができる。 [0035] In the production of an orally rapidly disintegrating tablet in the present invention, as described above, the lubricant may be mixed with other ingredients and then mixed with other ingredients, and then compression molded. The other It is possible to manufacture by the method of pre-coating and compression molding (external lubrication method) on the surface of the punch and the wall of the mortar without mixing with the ingredients of the mold, giving the desired hardness and disintegration can do. The method of applying the lubricant to the mortar can be performed by a conventionally known method or machine.
[0036] 本発明の口腔内速崩壊性錠剤は、通常 40〜200N、好ましくは 40〜150N、より 好ましくは 40〜120Nの硬度である。また、打錠圧は錠剤の大きさによって変わるた め、上述の硬度とするように打錠圧を適時調整することができる。直径 8mmの杵を用 い、 200mgの錠剤を打錠するとき、打錠圧力 300〜2400kgfのときに 40〜70Nの 硬度を有する。 [0036] The intraorally rapidly disintegrating tablet of the present invention has a hardness of usually 40 to 200N, preferably 40 to 150N, more preferably 40 to 120N. In addition, since the tableting pressure varies depending on the size of the tablet, the tableting pressure can be adjusted as appropriate to achieve the above-mentioned hardness. When a 200 mg tablet is compressed using a 8 mm diameter punch, it has a hardness of 40 to 70 N when the tableting pressure is 300 to 2400 kgf.
[0037] 本発明において、薬剤含量が多ぐ十分な硬度、良好な崩壊性並びに良好な成形 性を有することは、詳細は不明であるが、造粒粒子の性質 (構造と形状)を維持して いること、並びに特定の賦形剤、崩壊助剤及び Z又は結合剤自体の特性による造粒 粒子との相乗効果のためである考えられる。 [0037] In the present invention, it is unclear that the drug content has sufficient hardness, good disintegration property, and good moldability, but the properties (structure and shape) of the granulated particles are maintained. And the synergistic effect with the granulated particles due to the characteristics of certain excipients, disintegration aids and Z or the binder itself.
[0038] 本発明の口腔内速崩壊性錠剤は、速崩壊性を目的としたもの以外の錠剤 (例えば チユアブル錠)に成型するなど、他の固形製剤としても用いることができる。 [0038] The rapidly disintegrating tablet in the oral cavity of the present invention can also be used as other solid preparations such as molding into tablets other than those intended for rapid disintegrating (for example, tabletable tablets).
本発明の口腔内速崩壊性錠剤は、少量の水で直ちに崩壊することから、医薬品の みならず、食品や健康食品や特定機能食品、ペットフードや飼料、農薬に用いること も可能である。 Since the rapidly disintegrating tablet in the oral cavity of the present invention disintegrates immediately with a small amount of water, it can be used not only for pharmaceuticals but also for foods, health foods, specific function foods, pet foods, feeds and agricultural chemicals.
実施例 Example
[0039] 以下に、本発明を実施例により説明する力 これらの実施例は本発明の範囲を限 定するものではない。 [0039] In the following, the present invention will be described by way of examples. These examples do not limit the scope of the present invention.
実施例で得られた各錠剤にっ ヽての評価は、次の方法により行った。 Each tablet obtained in the examples was evaluated by the following method.
[口腔内崩壊時間] [Oral disintegration time]
錠剤(1錠ずつ n=6)を、 3〜8人の被験者が口腔内に入れてから完全に崩壊す るまでの時間を測定し、その平均値を口腔内崩壊時間とした。 The time from when 3 to 8 subjects put tablets (n = 6 each) into the oral cavity until they completely disintegrate was measured, and the average value was taken as the oral disintegration time.
[錠剤の硬度] [Tablet hardness]
ロードセル式錠剤硬度計〔PC— 30、岡田精ェ (株)製〕を用いて測定した。 [打錠障害]
打錠機の臼杵、打錠後の錠剤を観察し、ステイツキングやキヤッビングを評価した。 It was measured using a load cell type tablet hardness meter [PC-30, manufactured by Seida Okada Co., Ltd.]. [Tabletting disorder] The mortar of the tableting machine and the tablet after tableting were observed to evaluate the stateking and cabbing.
[0040] [比較例 1] 乾式混合後打錠 [0040] [Comparative Example 1] Tableting after dry mixing
噴霧乾燥造粒 D—マン-トール〔Pearlitol 200 SD、 Roquette社製〕 51. 2重量部、 キシリトール〔キシリット XC、東和化成工業 (株)製〕 3. 2重量部、クロスポビドン〔コリド ン CL、 BASF武田ビタミン (株)製〕 7. 2重量部、結晶セルロース〔セォラス PH— 101 、旭化成 (株)製〕 13. 6重量部、メタケイ酸アルミン酸マグネシウム〔ノイシリン UFL2、 富士化学工業 (株)製〕 4. 8重量部を混合し、アスピリン 20重量部を添加混合し、次 V、で適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機 [HT -API 8SS— II、(株)畑鉄工所製〕により、重量 200mg、直径 8mm、 9Rの錠剤を設定硬 度 50Nとして打錠した力 打錠中ステイツキングが生じ、錠剤を得ることはできなかつ た。 Spray-dried granulation D-Mann-Toll (Pearlitol 200 SD, Roquette) 51.2 parts by weight, Xylitol (Xylit XC, Towa Kasei Kogyo Co., Ltd.) 3.2 parts by weight, Crospovidone (Coridon CL, BASF Takeda Vitamin Co., Ltd.] 7.2 parts by weight, crystalline cellulose (Ceras PH-101, manufactured by Asahi Kasei Co., Ltd.) 13.6 parts by weight, magnesium aluminate metasilicate (Neusilin UFL2, manufactured by Fuji Chemical Industry Co., Ltd.) ] 4. Mix 8 parts by weight, add 20 parts by weight of aspirin, mix with appropriate amount of magnesium stearate in V, and then press rotary tableting machine [HT-API 8SS-II, Hata Tekko Co., Ltd.] The product produced by force was subjected to force-stamping during tableting with a tablet having a weight of 200 mg, a diameter of 8 mm, and a 9R tablet with a set hardness of 50 N, and the tablet could not be obtained.
[0041] [参考例 1] 造粒粒子の製造 [0041] [Reference Example 1] Production of granulated particles
マン-トール〔マンニット p、東和化成工業 (株)製〕 64重量部、キシリトール 4重量部 、クロスポビドン 9重量部、結晶セルロース 17重量部、メタケイ酸アルミン酸マグネシゥ ム 6重量部を水に均質に分散させたのち、噴霧乾燥機〔L— 8型、大川原化工機 (株) 製〕を用いて、出口温度 90°Cで噴霧乾燥し、流動性の良!、白色の球状の造粒粒子 を得た。 Mantol (Mannit p, manufactured by Towa Kasei Kogyo Co., Ltd.) 64 parts by weight, 4 parts by weight of xylitol, 9 parts by weight of crospovidone, 17 parts by weight of crystalline cellulose, 6 parts by weight of magnesium metasilicate aluminate in water And then spray-dried at an outlet temperature of 90 ° C using a spray dryer (L-8 type, manufactured by Okawara Kako Co., Ltd.). Good fluidity! White spherical granulated particles Got.
[0042] [比較例 2] [0042] [Comparative Example 2]
参考例 1で得られた造粒粒子 95重量部にアスピリン 5重量部を混合し、適量のステ アリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打 錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 5 parts by weight of aspirin with 95 parts by weight of the granulated particles obtained in Reference Example 1, and then mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
[0043] [実施例 1] [0043] [Example 1]
参考例 1で得られた造粒粒子 88重量部にアスピリン 5重量部、低置換度ヒドロキシ プロピルセルロース〔LH— Bl、信越化学工業 (株)製〕 1重量部、メタケイ酸アルミン 酸マグネシウム 1重量部及びクロスカルメロースナトリウム〔Kiccolate ND200、旭化成 製〕 5重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。
[0044] [実施例 2] 88 parts by weight of the granulated particles obtained in Reference Example 1 5 parts by weight of aspirin, low-substituted hydroxypropylcellulose [LH-Bl, manufactured by Shin-Etsu Chemical Co., Ltd.] 1 part by weight, magnesium aluminometasilicate 1 part by weight And croscarmellose sodium (Kiccolate ND200, manufactured by Asahi Kasei) After mixing 5 parts by weight and mixing an appropriate amount of magnesium stearate, the tablet was tableted using a rotary tableting machine with a set hardness of 50N, and weighed 200mg, diameter 8mm, 9R. Tablets were obtained. [0044] [Example 2]
参考例 1で得られた造粒粒子 88重量部にアスピリン 5重量部、ポリビニルピロリドン〔 コリドン 30、 BASF武田ビタミン (株)製〕 1重量部、メタケイ酸アルミン酸マグネシウム 1重量部及びクロスポビドン 5重量部を混合し、適量のステアリン酸マグネシウムを混 合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mmゝ 9Rの錠剤を得た。 88 parts by weight of the granulated particles obtained in Reference Example 1 and 5 parts by weight of aspirin, 1 part by weight of polyvinylpyrrolidone (Collidon 30, manufactured by BASF Takeda Vitamin Co., Ltd.), 1 part by weight of magnesium aluminate metasilicate and 5 parts by weight of crospovidone The parts were mixed and mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets with a weight of 200 mg and a diameter of 8 mm ゝ 9R.
[0045] [実施例 3] [0045] [Example 3]
参考例 1で得られた造粒粒子 88重量部にアスピリン 5重量部、ヒドロキシプロピルメ チルセルロース〔TC— 5R、信越化学工業 (株)製〕 1重量部、メタケイ酸アルミン酸マ グネシゥム 1重量部及びクロスポビドン 5重量部を混合し、適量のステアリン酸マグネ シゥムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200 mg、直径 8mm、 9Rの錠剤を得た。 88 parts by weight of the granulated particles obtained in Reference Example 1 5 parts by weight of aspirin, 1 part by weight of hydroxypropyl methylcellulose [TC-5R, manufactured by Shin-Etsu Chemical Co., Ltd.], 1 part by weight of magnesium aluminate metasilicate Then, 5 parts by weight of crospovidone was mixed and an appropriate amount of magnesium stearate was mixed, and then tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets having a weight of 200 mg, a diameter of 8 mm, and 9R.
[0046] [実施例 4] [Example 4]
参考例 1で得られた造粒粒子 88重量部にアスピリン 5重量部、ヒドロキシプロピルセ ルロース〔HPC SL、 日本曹達 (株)製〕 1重量部、ケィ酸カルシウム〔フローライト RE、 エーザィフードケミカル (株)製〕 1重量部及びクロスカルメロースナトリウム 5重量部を 混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設 定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 88 parts by weight of the granulated particles obtained in Reference Example 1 and 5 parts by weight of aspirin, 1 part by weight of hydroxypropylcellulose (HPC SL, Nippon Soda Co., Ltd.), calcium silicate (FLORITE RE, Eisai Food Chemical) (Made by Co., Ltd.) 1 part by weight and 5 parts by weight of croscarmellose sodium were mixed, mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50 N, weight 200 mg, diameter 8 mm, 9R tablets were obtained.
[0047] [比較例 3] [0047] [Comparative Example 3]
参考例 1で得られた造粒粒子 80重量部にアスピリン 20重量部を混合し、適量のス テアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして 打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 20 parts by weight of aspirin with 80 parts by weight of the granulated particles obtained in Reference Example 1, and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, and the weight was 200 mg, diameter. 8mm, 9R tablets were obtained.
[0048] [実施例 5] [0048] [Example 5]
参考例 1で得られた造粒粒子 60重量部にアスピリン 20重量部と結晶セルロース 20 重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機 により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 60 parts by weight of the granulated particles obtained in Reference Example 1 were mixed with 20 parts by weight of aspirin and 20 parts by weight of crystalline cellulose, mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0049] [実施例 6] [0049] [Example 6]
参考例 1で得られた造粒粒子 60重量部にアスピリン 20重量部とトウモロコシデンプ
ン〔日本コーンスターチ (株)製〕 20重量部を混合し、適量のステアリン酸マグネシウム を混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、 直径 8mmゝ 9Rの錠剤を得た。 60 parts by weight of the granulated particles obtained in Reference Example 1 and 20 parts by weight of aspirin and corn denp [Made by Nippon Corn Starch Co., Ltd.] After mixing 20 parts by weight and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets with a weight of 200mg and a diameter of 8mm ゝ 9R. It was.
[0050] [比較例 4] [0050] [Comparative Example 4]
参考例 1で得られた造粒粒子 60重量部にアスピリン 40重量部を混合し、適量のス テアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして 打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 60 parts by weight of the granulated particles obtained in Reference Example 1 with 40 parts by weight of aspirin and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
[0051] [実施例 7] [0051] [Example 7]
参考例 1で得られた造粒粒子 50重量部にアスピリン 40重量部と結晶セルロース 10 重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機 により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 50 parts by weight of the granulated particles obtained in Reference Example 1 are mixed with 40 parts by weight of aspirin and 10 parts by weight of crystalline cellulose, mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0052] [表 1] [0052] [Table 1]
[0053] 比較例 1が打錠障害を起こし、錠剤を得ることができな力つたことから、本発明で用 いる造粒粒子が重要な働きをしていることがわかる。実施例 1〜7と比較例 2〜4より、 本発明における賦形剤、崩壊助剤及び Z又は結合剤から選ばれる少なくとも 1種以 上を添加することによって、良好な崩壊性、良好な成形性及びより高い硬度とが得ら れることがゎカゝる。 [0053] Since Comparative Example 1 caused tableting trouble and was unable to obtain a tablet, it can be seen that the granulated particles used in the present invention play an important role. From Examples 1 to 7 and Comparative Examples 2 to 4, by adding at least one or more selected from excipients, disintegration aids and Z or binders in the present invention, good disintegration and good molding The higher the hardness and the higher the hardness.
[0054] [参考例 2] 造粒粒子の製造 [0054] [Reference Example 2] Production of granulated particles
マン-トール 65重量部、キシリトール 4重量部、クロスポビドン 9重量部、結晶セル口
ース 17重量部、無水リン酸水素カルシウム 5重量部を水に均質に分散させたのち、 噴霧乾燥機〔L— 8型、大川原化工機社 (株)製〕を用いて、出口温度 90°Cで噴霧乾 燥し、流動性の良い白色の球状の造粒粒子を得た。 Mantol 65 parts by weight, xylitol 4 parts by weight, crospovidone 9 parts by weight, crystal cell port 17 parts by weight and 5 parts by weight of anhydrous calcium hydrogen phosphate were uniformly dispersed in water, and then the outlet temperature was 90 ° using a spray dryer (L-8 type, manufactured by Okawara Chemical Co., Ltd.). Spray drying with C gave white spherical granulated particles with good fluidity.
[0055] [比較例 5] [0055] [Comparative Example 5]
参考例 2で得られた造粒粒子 90重量部にアスピリン 10重量部を混合し、適量のス テアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして 打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 Mix 90 parts by weight of the granulated particles obtained in Reference Example 2 with 10 parts by weight of aspirin, mix with an appropriate amount of magnesium stearate, and then press the tablet with a set hardness of 50 N using a rotary tableting machine. 8mm, 9R tablets were obtained.
[0056] [実施例 8] [0056] [Example 8]
参考例 2で得られた造粒粒子 70重量部にアスピリン 10重量部と低置換度ヒドロキ シプロピルセルロース 20重量部を混合し、適量のステアリン酸マグネシウムを混合し たのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8m m、 9Rの錠剤を得た。 70 parts by weight of the granulated particles obtained in Reference Example 2 are mixed with 10 parts by weight of aspirin and 20 parts by weight of low-substituted hydroxypropyl cellulose, mixed with an appropriate amount of magnesium stearate, and then set using a rotary tableting machine. Tableting was performed with a hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0057] [実施例 9] [0057] [Example 9]
クロスカルメロースナトリウム〔Ac-Dト Sol、旭化成 (株)製〕 50gと軽質無水ケィ酸〔ァ ドソリダ一— 101、フロイント産業 (株)製〕 50gを乳鉢にて、水を適量加えながら混練 した。これを 22メッシュの篩にて造粒し、 60°Cにて 18時間乾燥後に 22メッシュの篩 にて整粒し、顆粒 Aを得た。 Croscarmellose sodium (Ac-D To Sol, manufactured by Asahi Kasei Co., Ltd.) 50 g and light anhydrous caeic acid (Fad Solida 101, manufactured by Freund Sangyo Co., Ltd.) 50 g were kneaded in a mortar while adding an appropriate amount of water. . This was granulated with a 22 mesh sieve, dried at 60 ° C. for 18 hours, and then granulated with a 22 mesh sieve to obtain granules A.
参考例 2で得られた造粒粒子 80重量部にアスピリン 10重量部と顆粒 A10重量部を 混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設 定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 80 parts by weight of the granulated particles obtained in Reference Example 2 were mixed with 10 parts by weight of aspirin and 10 parts by weight of granules A, mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0058] [比較例 6] [0058] [Comparative Example 6]
参考例 2で得られた造粒粒子 80重量部にアスピリン 20重量部を混合し、適量のス テアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして 打錠し、重量 200mg、直径 8mm、 9R錠剤を得た。 After mixing 20 parts by weight of aspirin with 80 parts by weight of the granulated particles obtained in Reference Example 2 and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, and the weight was 200 mg, diameter. 8mm, 9R tablets were obtained.
[0059] [実施例 10] [Example 10]
参考例 2で得られた造粒粒子 70重量部にアスピリン 20重量部とクロスカルメロース ナトリウム 10重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロー タリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤
を得た。 Mix 70 parts by weight of the granulated particles obtained in Reference Example 2 with 20 parts by weight of aspirin and 10 parts by weight of croscarmellose sodium, mix with an appropriate amount of magnesium stearate, and then set the hardness to 50 N using a rotary tableting machine. Tablet, weight 200mg, diameter 8mm, 9R tablet Got.
[0060] [実施例 11] [0060] [Example 11]
参考例 2で得られた造粒粒子 60重量部にアスピリン 20重量部とカルメロース〔NS — 300、五徳薬品製〕 20重量部を混合し、適量のステアリン酸マグネシウムを混合し たのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8m m、 9Rの錠剤を得た。 60 parts by weight of the granulated particles obtained in Reference Example 2 are mixed with 20 parts by weight of aspirin and 20 parts by weight of carmellose (NS-300, manufactured by Gotoku Pharmaceutical) and mixed with an appropriate amount of magnesium stearate, followed by rotary tableting. Tableting was performed using a machine with a set hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0061] [実施例 12] [0061] [Example 12]
参考例 2で得られた造粒粒子 60重量部にアスピリン 20重量部と結晶セルロース 20 重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機 により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 60 parts by weight of the granulated particles obtained in Reference Example 2 were mixed with 20 parts by weight of aspirin and 20 parts by weight of crystalline cellulose, mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0062] [実施例 13] [0062] [Example 13]
参考例 2で得られた造粒粒子 32重量部にアスピリン 20重量部と結晶セルロース 48 重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機 により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 Mix 32 parts by weight of the granulated particles obtained in Reference Example 2 with 20 parts by weight of aspirin and 48 parts by weight of crystalline cellulose, mix with an appropriate amount of magnesium stearate, and then tablet with a rotary tableting machine with a set hardness of 50N. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0063] [実施例 14] [0063] [Example 14]
参考例 2で得られた造粒粒子 70重量部にアスピリン 20重量部とトウモロコシデンプ ン 10重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 70 parts by weight of the granulated particles obtained in Reference Example 2 are mixed with 20 parts by weight of aspirin and 10 parts by weight of corndenpene, mixed with an appropriate amount of magnesium stearate, and then tableted using a rotary tableting machine with a set hardness of 50N. As a result, a tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0064] [比較例 7] [0064] [Comparative Example 7]
参考例 2で得られた造粒粒子 70重量部にアスピリン 30重量部を混合し、適量のス テアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして 打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 70 parts by weight of the granulated particles obtained in Reference Example 2 with 30 parts by weight of aspirin and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
[0065] [実施例 15] [0065] [Example 15]
参考例 2で得られた造粒粒子 60重量部にアスピリン 30重量部とクロスポビドン 10 重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機 により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 60 parts by weight of the granulated particles obtained in Reference Example 2 were mixed with 30 parts by weight of aspirin and 10 parts by weight of crospovidone, mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0066] [比較例 8]
参考例 2で得られた造粒粒子 60重量部にアスピリン 40重量部を混合し、適量のス テアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして 打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 [0066] [Comparative Example 8] After mixing 60 parts by weight of the granulated particles obtained in Reference Example 2 with 40 parts by weight of aspirin and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
[0067] [実施例 16] [0067] [Example 16]
参考例 2で得られた造粒粒子 50重量部にアスピリン 40重量部とカルメロース 10重 量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機に より設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 Mix 50 parts by weight of the granulated particles obtained in Reference Example 2 with 40 parts by weight of aspirin and 10 parts by weight of carmellose, mix with an appropriate amount of magnesium stearate, and then press the tablet with a set hardness of 50 N using a rotary tableting machine. As a result, a tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0068] [実施例 17] [0068] [Example 17]
参考例 2で得られた造粒粒子 40重量部にアスピリン 40重量部とトウモロコシデンプ ン 20重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 40 parts by weight of the granulated particles obtained in Reference Example 2 are mixed with 40 parts by weight of aspirin and 20 parts by weight of corndenpene, mixed with an appropriate amount of magnesium stearate, and then tableted using a rotary tableting machine with a set hardness of 50N. As a result, a tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0069] [実施例 18] [0069] [Example 18]
参考例 2で得られた造粒粒子 40重量部にアスピリン 40重量部とコメデンプン〔ミクロ パール、島田化学工業 (株)製〕 20重量部を混合し、適量のステアリン酸マグネシゥ ムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg 、直径 8mmゝ 9Rの錠剤を得た。 After mixing 40 parts by weight of the granulated particles obtained in Reference Example 2 with 40 parts by weight of aspirin and 20 parts by weight of rice starch (Micropearl, manufactured by Shimada Chemical Co., Ltd.), an appropriate amount of magnesium stearate is mixed. Then, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine to obtain tablets having a weight of 200 mg and a diameter of 8 mm ゝ 9R.
[0070] [実施例 19] [0070] [Example 19]
参考例 2で得られた造粒粒子 50重量部にアスピリン 40重量部とクロスポビドン 10 重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機 により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 50 parts by weight of the granulated particles obtained in Reference Example 2 with 40 parts by weight of aspirin and 10 parts by weight of crospovidone, and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine. A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0071] [表 2]
打圧 錠剤硬度 打錠障害 口腔内崩壊試験 [0071] [Table 2] Tableting pressure Tablet hardness Tableting disorder Oral disintegration test
[kgf] [N] [sec] [kgf] [N] [sec]
比較例 5 440-470 50.9 なし 54.7 Comparative Example 5 440-470 50.9 None 54.7
実施例 8 540-635 40.9 なし 37.8 Example 8 540-635 40.9 None 37.8
実施例 9 470-507 49.4 なし 21.1 Example 9 470-507 49.4 None 21.1
比較例 6 360-380 41.6 なし 98.9 Comparative Example 6 360-380 41.6 None 98.9
実施例 1 0 45.1 なし 36.5 Example 1 0 45.1 None 36.5
実施例 1 1 560-595 41.0 なし 18.0 Example 1 1 560-595 41.0 None 18.0
実施例 1 2 336-365 49.1 なし 21.2 Example 1 2 336-365 49.1 None 21.2
実施例 1 3 205-225 44.6 なし 23.2 Example 1 3 205-225 44.6 None 23.2
実施例 1 4 500-540 48.1 なし 26.2 Example 1 4 500-540 48.1 None 26.2
比較例 7 425-460 48.0 杵に付着あり 210.9 Comparative Example 7 425-460 48.0
実施例 1 5 698-791 44.9 なし 32.6 Example 1 5 698-791 44.9 None 32.6
比較例 8 425-460 48.0 杵に付着あり 210.9 Comparative Example 8 425-460 48.0
実施例 1 6 680-470 43.6 なし 21.2 Example 1 6 680-470 43.6 None 21.2
実施例 1 7 890-960 49.2 なし 22.8 Example 1 7 890-960 49.2 None 22.8
実施例 1 8 490-530 57.7 なし 21.2 Example 1 8 490-530 57.7 None 21.2
実施例 1 9 580-610 41.6 なし 1 9.1 Example 1 9 580-610 41.6 None 1 9.1
[0072] 表 2の結果より、本発明における造粒粒子に賦形剤、崩壊助剤及び Z又は結合剤 力 選ばれる少なくとも 1種以上を添加することによって、薬剤の含有量を多くしても より高い硬度としながら良好な崩壊性、良好な成形性が得られることがわかる。 [0072] From the results of Table 2, it is possible to increase the content of the drug by adding at least one selected from excipients, disintegration aids, and Z or binder force to the granulated particles in the present invention. It can be seen that good disintegration and good moldability can be obtained with higher hardness.
[0073] [参考例 3] 造粒粒子の製造 [0073] [Reference Example 3] Production of granulated particles
マン-トール〔マンニット p、東和化成工業 (株)製〕 65重量部、キシリトール 5重量部 、クロスポビドン 8重量部、結晶セルロース 15重量部、メタケイ酸アルミン酸マグネシゥ ム 7重量部を水に均質に分散させたのち、噴霧乾燥機〔L— 8型、大川原化工機 (株) 製〕を用いて、出口温度 80°Cで噴霧乾燥し、流動性の良!、白色の球状の造粒粒子 を得た。 Mantol (Mannit p, manufactured by Towa Kasei Kogyo Co., Ltd.) 65 parts by weight, xylitol 5 parts by weight, crospovidone 8 parts by weight, crystalline cellulose 15 parts by weight, magnesium metasilicate aluminate 7 parts by weight in water And then spray-dried at an outlet temperature of 80 ° C using a spray dryer (L-8 type, manufactured by Okawahara Kako Co., Ltd.). Good fluidity! White spherical granulated particles Got.
[0074] [比較例 9] [0074] [Comparative Example 9]
参考例 3で得られた造粒粒子 70重量部にァセトァミノフェン 30重量部を混合し、適 量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50 Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 70 parts by weight of the granulated particles obtained in Reference Example 3 with 30 parts by weight of acetaminophen and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0075] [実施例 20] [0075] [Example 20]
参考例 3で得られた造粒粒子 65重量部にァセトァミノフェン 30重量部とカルメロ一
ス 5重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た 65 parts by weight of the granulated particles obtained in Reference Example 3 and 30 parts by weight of acetaminophen and carmello After mixing 5 parts by weight and a suitable amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
[0076] [実施例 21] [0076] [Example 21]
参考例 3で得られた造粒粒子 50重量部にァセトァミノフェン 30重量部とヒドロキシ プロピルセルロース 20重量部を混合し、適量のステアリン酸マグネシウムを混合した のち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm ゝ 9Rの錠剤を得た。 50 parts by weight of the granulated particles obtained in Reference Example 3 are mixed with 30 parts by weight of acetaminophen and 20 parts by weight of hydroxypropyl cellulose, mixed with an appropriate amount of magnesium stearate, and then set to a hardness of 50 N using a rotary tableting machine. As a result, tablets having a weight of 200 mg and a diameter of 8 mmmm9R were obtained.
[0077] [実施例 22] [0077] [Example 22]
参考例 3で得られた造粒粒子 50重量部にァセトァミノフェン 30重量部とカルメロ一 ス 20重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た 50 parts by weight of the granulated particles obtained in Reference Example 3 are mixed with 30 parts by weight of acetaminophen and 20 parts by weight of carmellose, mixed with an appropriate amount of magnesium stearate, and then set to a hardness of 50 N using a rotary tableting machine. As a result, tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0078] [比較例 10] [0078] [Comparative Example 10]
参考例 3で得られた造粒粒子 50重量部にァセトァミノフェン 50重量部を混合し、適 量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50 N、重量 200mg、直径 8mm、 9Rとして打錠を試みた力 打錠機の上限打圧 2400k gfを超え装置が停止したたため、錠剤を得ることはできな力つた。 After mixing 50 parts by weight of acetaminophen with 50 parts by weight of the granulated particles obtained in Reference Example 3 and mixing an appropriate amount of magnesium stearate, the rotary tableting machine sets the hardness to 50 N, weight 200 mg, diameter. Force to try tableting as 8mm, 9R The upper limit pressure of the tableting machine exceeded 2400k gf, and the machine stopped, so it was impossible to obtain tablets.
[0079] [実施例 23] [0079] [Example 23]
参考例 3で得られた造粒粒子 50重量部にァセトァミノフェン 40重量部とクロスポビ ドン 10重量部を混合し、適量のフマル酸ステアリルナトリウムを混合したのち、ロータ リー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤 を得た。 After mixing 50 parts by weight of the granulated particles obtained in Reference Example 3 with 40 parts by weight of acetaminophen and 10 parts by weight of crospovidone, mixing an appropriate amount of sodium stearyl fumarate, and then setting the hardness with a rotary tableting machine. Tableting was performed as 50N to obtain a tablet having a weight of 200 mg, a diameter of 8 mm, and 9R.
[0080] [実施例 24] [0080] [Example 24]
参考例 3で得られた造粒粒子 20重量部にァセトァミノフェン 50重量部とカルメロ一 ス 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た
[0081] [実施例 25] After mixing 20 parts by weight of the granulated particles obtained in Reference Example 3 with 50 parts by weight of acetaminophen and 30 parts by weight of carmellose, mixing an appropriate amount of magnesium stearate, and setting the hardness to 50 N using a rotary tableting machine. As a result, tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained. [0081] [Example 25]
参考例 3で得られた造粒粒子 20重量部にァセトァミノフェン 50重量部とコメデンプ ン 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 After mixing 20 parts by weight of the granulated particles obtained in Reference Example 3 with 50 parts by weight of acetaminophen and 30 parts by weight of comedenpene, mixing an appropriate amount of magnesium stearate, and setting the hardness to 50 N using a rotary tableting machine. Tableting was performed to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
[0082] [実施例 26] [Example 26]
参考例 3で得られた造粒粒子 20重量部にァセトァミノフェン 50重量部とトウモロコシ デンプン 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロー タリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤 を得た。 After mixing 20 parts by weight of the granulated particles obtained in Reference Example 3 with 50 parts by weight of acetaminophen and 30 parts by weight of corn starch, mixing an appropriate amount of magnesium stearate, and then setting the hardness to 50 N using a rotary tableting machine. As a result, tablets having a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0083] [実施例 27] [0083] [Example 27]
参考例 3で得られた造粒粒子 20重量部にァセトァミノフェン 50重量部とコメデンプ ン 20重量部とトウモロコシデンプン 10重量部を混合し、適量のステアリン酸マグネシ ゥムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200m g、直径 8mm、 9Rの淀剤を得た。 After mixing 20 parts by weight of the granulated particles obtained in Reference Example 3 with 50 parts by weight of acetaminophen, 20 parts by weight of comedenpene and 10 parts by weight of corn starch, and then mixing an appropriate amount of magnesium stearate, rotary Tableting was performed using a tableting machine with a set hardness of 50N, and a glaze having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0084] [実施例 28] [0084] [Example 28]
参考例 3で得られた造粒粒子 10重量部にァセトァミノフェン 60重量部と結晶セル口 ース 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 Mix 60 parts by weight of acetaminophen and 30 parts by weight of crystal cell mouth with 10 parts by weight of the granulated particles obtained in Reference Example 3, mix with an appropriate amount of magnesium stearate, and set using a rotary tableting machine. Tableting was performed with a hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0085] [実施例 29] [0085] [Example 29]
参考例 3で得られた造粒粒子 10重量部にァセトァミノフェン 60重量部とカルメロ一 ス 10重量部とコメデンプン 20重量部を混合し、適量のステアリン酸マグネシウムを混 合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mmゝ 9Rの錠剤を得た。 After mixing 10 parts by weight of the granulated particles obtained in Reference Example 3 with 60 parts by weight of acetaminophen, 10 parts by weight of carmellose and 20 parts by weight of rice starch, and then mixing an appropriate amount of magnesium stearate, Tableting was performed using a tableting machine with a set hardness of 50 N, and tablets with a weight of 200 mg and a diameter of 8 mm ゝ 9R were obtained.
[0086] [実施例 30] [0086] [Example 30]
参考例 3で得られた造粒粒子 10重量部にァセトァミノフェン 60重量部とクロスポビ ドン 25重量部と結晶セルロース 5重量部を混合し、適量のステアリン酸マグネシウム
を混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、 直径 8mmゝ 9Rの錠剤を得た。 Mix 10 parts by weight of the granulated particles obtained in Reference Example 3 with 60 parts by weight of acetaminophen, 25 parts by weight of crospovidone and 5 parts by weight of crystalline cellulose, and add an appropriate amount of magnesium stearate. After mixing, the tablets were tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets having a weight of 200 mg and a diameter of 8 mm ゝ 9R.
[0087] [表 3] [0087] [Table 3]
[0088] 表 3の結果より、本発明における造粒粒子に賦形剤、崩壊助剤及び Z又は結合剤 力 選ばれる少なくとも 1種以上を添加することによって、薬剤の含有量を多くしても より高い硬度としながら良好な崩壊性、良好な成形性が得られることがわかる。 [0088] From the results shown in Table 3, the content of the drug can be increased by adding at least one selected from the group consisting of excipient, disintegration aid and Z or binder force to the granulated particles in the present invention. It can be seen that good disintegration and good moldability can be obtained with higher hardness.
[0089] [参考例 4] 造粒粒子の製造 [0089] [Reference Example 4] Production of granulated particles
マン-トール 65重量部、キシリトール 5重量部、クロスポビドン 8重量部、結晶セル口 ース 18重量部、無水リン酸水素カルシウム 4重量部を水に均質に分散させたのち、 噴霧乾燥機〔L— 8型、大川原化工機社 (株)製〕を用いて、出口温度 80°Cで噴霧乾 燥し、流動性の良い白色の球状の造粒粒子を得た。 After uniformly dispersing 65 parts by weight of mantol, 5 parts by weight of xylitol, 8 parts by weight of crospovidone, 18 parts by weight of the crystal cell mouth and 4 parts by weight of anhydrous calcium hydrogen phosphate, spray dryer [L — 8 type, manufactured by Okawara Chemical Industries Co., Ltd.] was spray-dried at an outlet temperature of 80 ° C. to obtain white spherical granulated particles with good fluidity.
[0090] [比較例 11] [0090] [Comparative Example 11]
参考例 4で得られた造粒粒子 80重量部にァセトァミノフェン 20重量部を混合し、適 量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50 Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 20 parts by weight of acetaminophen with 80 parts by weight of the granulated particles obtained in Reference Example 4, and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0091] [実施例 31] [0091] [Example 31]
参考例 4で得られた造粒粒子 64重量部にァセトァミノフェン 20重量部と結晶セル口
ース 16重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 The granulated particles obtained in Reference Example 4 are mixed with 64 parts by weight of acetaminophen 20 parts by weight and a crystal cell port. After mixing 16 parts by weight of the cellulose and an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
[0092] [比較例 12] [0092] [Comparative Example 12]
参考例 4で得られた造粒粒子 70重量部にァセトァミノフェン 30重量部を混合し、適 量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50 Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 70 parts by weight of the granulated particles obtained in Reference Example 4 with 30 parts by weight of acetaminophen and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0093] [実施例 32] [0093] [Example 32]
参考例 4で得られた造粒粒子 65重量部にァセトァミノフェン 30重量部とクロスポビ ドン 5重量部を混合し、適量のフマル酸ステアリルナトリウムを混合したのち、ロータリ 一打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を 得た。 Mix 65 parts by weight of the granulated particles obtained in Reference Example 4 with 30 parts by weight of acetaminophen and 5 parts by weight of crospovidone, mix an appropriate amount of sodium stearyl fumarate, and then set the hardness with a rotary tableting machine. Tableting was performed as 50N to obtain tablets having a weight of 200 mg, a diameter of 8 mm, and 9R.
[0094] [実施例 33] [0094] [Example 33]
参考例 4で得られた造粒粒子 50重量部にァセトァミノフェン 30重量部とカルメロ一 ス 20重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た After mixing 50 parts by weight of the granulated particles obtained in Reference Example 4 with 30 parts by weight of acetaminophen and 20 parts by weight of carmellose and mixing an appropriate amount of magnesium stearate, the set hardness is set to 50 N using a rotary tableting machine. As a result, tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0095] [比較例 13] [0095] [Comparative Example 13]
参考例 4で得られた造粒粒子 60重量部にァセトァミノフェン 40重量部を混合し、適 量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50 Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 40 parts by weight of acetaminophen with 60 parts by weight of the granulated particles obtained in Reference Example 4, and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, A tablet having a weight of 200 mg, a diameter of 8 mm, and 9R was obtained.
[0096] [実施例 34] [0096] [Example 34]
参考例 4で得られた造粒粒子 35重量部にァセトァミノフェン 40重量部と結晶セル口 ース 25重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 Mix 35 parts by weight of the granulated particles obtained in Reference Example 4 with 40 parts by weight of acetaminophen and 25 parts by weight of crystal cell mouth, mix with an appropriate amount of magnesium stearate, and set with a rotary tableting machine. Tableting was performed with a hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0097] [実施例 35] [0097] [Example 35]
参考例 4で得られた造粒粒子 35重量部にァセトァミノフェン 40重量部とコメデンプ
ン 25重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 35 parts by weight of the granulated particles obtained in Reference Example 4 and 40 parts by weight of acetaminophen 25 parts by weight of the mixture was mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50 N to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
[0098] [実施例 36] [0098] [Example 36]
参考例 4で得られた造粒粒子 35重量部にァセトァミノフェン 40重量部、コメデンプ ン 20重量部及び結晶セルロース 5重量部を混合し、適量のステアリン酸マグネシウム を混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、 直径 8mmゝ 9Rの錠剤を得た。 Mix 35 parts by weight of the granulated particles obtained in Reference Example 4 with 40 parts by weight of acetaminophen, 20 parts by weight of comedenpene and 5 parts by weight of crystalline cellulose, mix with an appropriate amount of magnesium stearate, and then perform rotary tableting. Tableting was performed using a machine with a set hardness of 50 N, and tablets with a weight of 200 mg and a diameter of 8 mm 9 R were obtained.
[0099] [実施例 37] [0099] [Example 37]
参考例 4で得られた造粒粒子 35重量部にァセトァミノフェン 40重量部、コメデンプ ン 20重量部及びカルメロース 5重量部を混合し、適量のステアリン酸マグネシウムを 混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直 径 8mmゝ 9Rの錠剤を得た。 Mix 35 parts by weight of the granulated particles obtained in Reference Example 4 with 40 parts by weight of acetaminophen, 20 parts by weight of comedenpene and 5 parts by weight of carmellose, mix with an appropriate amount of magnesium stearate, and then use a rotary tableting machine. Was tableted with a set hardness of 50N, and tablets with a weight of 200mg and a diameter of 8mm ゝ 9R were obtained.
[0100] [実施例 38] [0100] [Example 38]
参考例 4で得られた造粒粒子 35重量部にァセトァミノフェン 40重量部、カルメロ一 ス 25重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た Mix 35 parts by weight of the granulated particles obtained in Reference Example 4 with 40 parts by weight of acetaminophen and 25 parts by weight of carmellose, mix with an appropriate amount of magnesium stearate, and then set the hardness to 50 N using a rotary tableting machine. To obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R
[0101] [比較例 14] [0101] [Comparative Example 14]
参考例 4で得られた造粒粒子 50重量部にァセトァミノフェン 50重量部を混合し、適 量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50 N、重量 200mg、直径 8mm、 9Rとして打錠を試みた力 打錠機の上限打圧 2400k gfを超え装置が停止したため、錠剤を得ることはできな力 た。 After mixing 50 parts by weight of acetaminophen with 50 parts by weight of the granulated particles obtained in Reference Example 4 and mixing an appropriate amount of magnesium stearate, the hardness is set to 50 N with a rotary tableting machine, weight 200 mg, diameter. Force to try tableting as 8mm and 9R The upper limit pressure of the tableting machine exceeded 2400kgf and the machine stopped, so it was impossible to obtain tablets.
[0102] [実施例 39] [0102] [Example 39]
参考例 4で得られた造粒粒子 20重量部にァセトァミノフェン 50重量部、コメデンプ ン 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。
[0103] [実施例 40] After mixing 20 parts by weight of the granulated particles obtained in Reference Example 4 with 50 parts by weight of acetoaminophene and 30 parts by weight of comedenpene, and mixing an appropriate amount of magnesium stearate, the rotary tablet press sets the hardness to 50N. Tableting was performed to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R. [0103] [Example 40]
参考例 4で得られた造粒粒子 20重量部にァセトァミノフェン 50重量部、カルメロ ス 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 Λ After mixing 20 parts by weight of the granulated particles obtained in Reference Example 4 with 50 parts by weight of acetoaminophen and 30 parts by weight of carmellose, and mixing an appropriate amount of magnesium stearate, the mixture is beaten to a set hardness of 50 N using a rotary tablet machine. Tablets to obtain tablets with a weight of 200mg, a diameter of 8mm, and 9R
[0104] [実施例 41] [Example 41]
参考例 4で得られた造粒粒子 10重量部にァセトァミノフェン 60重量部、カルメロ ス 10重量部とコメデンプン 20重量部を混合し、適量のステアリン酸マグネシウムを 2 合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直 ί 8mmゝ 9Rの錠剤を得た。 After mixing 10 parts by weight of the granulated particles obtained in Reference Example 4 with 60 parts by weight of acetaminophen, 10 parts by weight of carmellose and 20 parts by weight of rice starch, and combining two appropriate amounts of magnesium stearate, Tableting was performed with a tableting machine with a set hardness of 50 N, and tablets with a weight of 200 mg and a straightness of 8 mm 9 R were obtained.
[0105] [実施例 42] [0105] [Example 42]
参考例 4で得られた造粒粒子 10重量部にァセトァミノフェン 60重量部、カルメロ ス 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た Mix 10 parts by weight of the granulated particles obtained in Reference Example 4 with 60 parts by weight of acetaminophen and 30 parts by weight of carmellose, mix with an appropriate amount of magnesium stearate, and then press the rotary tablet to set the hardness to 50N. Tablets were obtained with a weight of 200 mg, diameter 8 mm, and 9R.
[0106] [表 4] [0106] [Table 4]
打圧 錠剤硬度 打錠障害 口腔内崩壊試験 [kgf] [N] [sec] 比較例 1 1 620-650 55.9 なし 84 実施例 31 480-510 52.5 なし 22 比較例 1 2 820-900 51.1 なし 167 実施例 32 1 1 10-1260 50.4 なし 21 実施例 33 1 180-1280 44.7 なし 25 比較例 1 3 2280-2376 43.0 杵に付着あり 298 実施例 34 680-730 55.2 なし 18 Tableting pressure Tablet hardness Tableting disorder Oral disintegration test [kgf] [N] [sec] Comparative example 1 1 620-650 55.9 None 84 Example 31 480-510 52.5 None 22 Comparative example 1 2 820-900 51.1 None 167 Example 32 1 1 10-1260 50.4 None 21 Example 33 1 180-1280 44.7 None 25 Comparative example 1 3 2280-2376 43.0 Sticking to heel 298 Example 34 680-730 55.2 None 18
実施例 35 600-670 55.3 なし 23 Example 35 600-670 55.3 None 23
実施例 36 580-630 50.0 なし 22 Example 36 580-630 50.0 None 22
実施例 37 690-730 55.1 なし 24 Example 37 690-730 55.1 None 24
実施例 38 660-730 58.2 なし 21 Example 38 660-730 58.2 None 21
比較例 1 4 2400超過 ― 打錠不可 ― 実施例 39 760-900 49.3 なし 24 Comparative example 1 4 Exceeding 2400-Untabletable-Example 39 760-900 49.3 None 24
実施例 40 780-870 58.0 なし 18 Example 40 780-870 58.0 None 18
実施例 41 800-899 48.9 なし 1 9 Example 41 800-899 48.9 None 1 9
実施例 42 2000-2290 66.2 なし 27
[0107] 表 4の結果より、本発明における造粒粒子に賦形剤、崩壊助剤及び Z又は結合剤 力 選ばれる少なくとも 1種以上を添加することによって、薬剤の含有量を多くしても より高い硬度としながらも非常に良好な崩壊性、良好な成形性が得られることがわか る。 Example 42 2000-2290 66.2 None 27 [0107] From the results shown in Table 4, it is possible to increase the content of the drug by adding at least one selected from excipients, disintegration aids and Z or binder force to the granulated particles in the present invention. It can be seen that very good disintegration and good moldability can be obtained with higher hardness.
[0108] [参考例 5] 薬剤を含む造粒粒子の製造 [0108] [Reference Example 5] Production of granulated particles containing drug
マン-トール 64. 5重量部、キシリトール 5重量部、クロスポビドン 8重量部、結晶セ ルロース 18重量部、無水リン酸水素カルシウム 4重量部、塩酸口ペラミド(日本薬局 方外医薬品規格) 0. 5重量部を水に均質に分散させたのち、噴霧乾燥機 (L 8型、 大川原化工機社製)を用いて、出口温度 90°Cで噴霧乾燥し、流動性の良い白色の 球状の造粒粒子を得た。 Manthol 64.5 parts by weight, xylitol 5 parts by weight, crospovidone 8 parts by weight, crystalline cellulose 18 parts by weight, anhydrous calcium hydrogen phosphate 4 parts by weight, oral peramide hydrochloride (Japanese Pharmacopoeia Standards for Foreign Drugs) 0.5 After homogeneously dispersing parts by weight in water, using a spray dryer (L 8 type, manufactured by Okawahara Chemical Co., Ltd.), spray-drying at an outlet temperature of 90 ° C, and white spherical granule with good fluidity Particles were obtained.
[0109] [比較例 15] [Comparative Example 15]
参考例 5で得られた造粒粒子に適量のステアリン酸マグネシウムを混合したのち、 ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの 錠剤を得た。 The granulated particles obtained in Reference Example 5 were mixed with an appropriate amount of magnesium stearate, and then tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
[0110] [実施例 43] [0110] [Example 43]
参考例 5で得られた造粒粒子 80重量部にヒドロキシプロピルスターチ 20重量部を 混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設 定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 20 parts by weight of hydroxypropyl starch with 80 parts by weight of the granulated particles obtained in Reference Example 5 and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, and the weight is 200 mg. A tablet with a diameter of 8 mm and 9R was obtained.
[0111] [実施例 44] [0111] [Example 44]
参考例 5で得られた造粒粒子 93重量部にヒドロキシプロピルセルロース 1重量部、 メタケイ酸アルミン酸マグネシウム 1重量部及びクロスポビドン 5重量部を混合し、適 量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50 Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 93 parts by weight of the granulated particles obtained in Reference Example 5 with 1 part by weight of hydroxypropyl cellulose, 1 part by weight of magnesium aluminate metasilicate and 5 parts by weight of crospovidone, and mixing an appropriate amount of magnesium stearate, Tableting was performed using a rotary tableting machine with a set hardness of 50 N, and tablets with a weight of 200 mg, a diameter of 8 mm, and 9R were obtained.
[0112] [実施例 45] [0112] [Example 45]
クロスポビドン 5g、トレハロース〔旭化成 (株)製〕 10g及び参考例 5で得られた造粒 粒子 85gを乳鉢にて、エタノール(99. 5%)を適量カ卩えながら混練した。これを 22メ ッシュの篩にて造粒し、 60°Cにて 18時間乾燥後に 22メッシュの篩にて整粒し、顆粒 Bを得た。
顆粒 Bに適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設 定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 Crospovidone 5 g, trehalose [manufactured by Asahi Kasei Co., Ltd.] 10 g and the granulated particles 85 g obtained in Reference Example 5 were kneaded in a mortar with ethanol (99.5%) in an appropriate amount. This was granulated with a 22 mesh sieve, dried at 60 ° C. for 18 hours, and then granulated with a 22 mesh sieve to obtain granules B. After mixing an appropriate amount of magnesium stearate with granule B, the tablet was tableted with a setting hardness of 50 N using a rotary tableting machine to obtain tablets of weight 200 mg, diameter 8 mm, 9R.
[0113] [実施例 46] [0113] [Example 46]
クロスポビドン 50gとマルチトール〔東和化成工業 (株)製〕 10gを乳鉢にて、エタノー ル(99. 5%)を適量カ卩えながら混練した。これを 22メッシュの篩にて造粒し、 60°Cに て 18時間乾燥後に 22メッシュの篩にて整粒し、顆粒 Cを得た。 Crospovidone (50 g) and maltitol (manufactured by Towa Kasei Kogyo Co., Ltd.) (10 g) were kneaded in a mortar while preparing an appropriate amount of ethanol (99.5%). This was granulated with a 22 mesh sieve, dried at 60 ° C. for 18 hours, and then granulated with a 22 mesh sieve to obtain granules C.
参考例 5で得られた造粒粒子 88重量部に顆粒 C12重量部を混合し、適量のステアリ ン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠 し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 88 parts by weight of the granulated particles obtained in Reference Example 5 with 12 parts by weight of granules C and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, weight 200 mg, diameter 8mm, 9R tablets were obtained.
[0114] [実施例 47] [0114] [Example 47]
クロスポビドン 10gと参考例 5で得られた造粒粒子 90gを乳鉢にて、エタノール (99 . 5%)を適量カ卩えながら混練した。これを 22メッシュの篩にて造粒し、 60°Cにて 18 時間乾燥後に 22メッシュの篩にて整粒し、顆粒 Dを得た。 10 g of crospovidone and 90 g of the granulated particles obtained in Reference Example 5 were kneaded in a mortar while adding an appropriate amount of ethanol (99.5%). This was granulated with a 22-mesh sieve, dried at 60 ° C for 18 hours, and then sized with a 22-mesh sieve to obtain granules D.
顆粒 Dに適量のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設 定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After an appropriate amount of magnesium stearate was mixed with granule D, it was tableted with a rotary tableting machine with a set hardness of 50N to obtain tablets with a weight of 200 mg, a diameter of 8 mm, and 9R.
[0115] [実施例 48] [0115] [Example 48]
クロスポビドン 50gとマルチトール 50gとメタケイ酸アルミン酸マグネシウム 10gを乳 鉢にて、エタノール(99. 5%)を適量カ卩えながら混練した。これを 22メッシュの篩にて 造粒し、 60°Cにて 18時間乾燥後に 22メッシュの篩にて整粒し、顆粒 Eを得た。 50 g of crospovidone, 50 g of maltitol, and 10 g of magnesium aluminate metasilicate were kneaded in a mortar while adding an appropriate amount of ethanol (99.5%). This was granulated with a 22 mesh sieve, dried at 60 ° C for 18 hours, and then sized with a 22 mesh sieve to obtain granules E.
参考例 5で得られた造粒粒子 89重量部に顆粒 El 1重量部を混合し、適量のステアリ ン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠 し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 1 part by weight of granule El with 89 parts by weight of the granulated particles obtained in Reference Example 5 and mixing an appropriate amount of magnesium stearate, the tablet was tableted with a set hardness of 50 N using a rotary tableting machine, and the weight was 200 mg. Tablets with a diameter of 8 mm and 9R were obtained.
[0116] [実施例 49] [0116] [Example 49]
クロスポビドン 5g、マルチトール 20g、メタケイ酸アルミン酸マグネシウム 5g及びヒド ロキシプロピルスターチ 70gを乳鉢にて、エタノール(99. 5%)を適量カ卩えながら混 練した。これを 22メッシュの篩にて造粒し、 60°Cにて 18時間乾燥後に 22メッシュの 篩にて整粒し、顆粒 Fを得た。 Crospovidone (5 g), maltitol (20 g), magnesium metasilicate aluminate (5 g) and hydroxypropyl starch (70 g) were mixed with an appropriate amount of ethanol (99.5%) in a mortar. This was granulated with a 22 mesh sieve, dried at 60 ° C for 18 hours, and then granulated with a 22 mesh sieve to obtain granules F.
参考例 5で得られた造粒粒子 90重量部に顆粒 F10重量部を混合し、適量のステアリ
ン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠 し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 Mix 90 parts by weight of the granulated particles obtained in Reference Example 5 with 10 parts by weight of granule F, After mixing the magnesium acid, the tablet was tableted with a set hardness of 50N using a rotary tableting machine to obtain tablets with a weight of 200mg, a diameter of 8mm and 9R.
[0117] [表 5] [0117] [Table 5]
[0118] 表 5の結果より、本発明における造粒粒子に賦形剤、崩壊助剤及び Z又は結合剤 力 選ばれる少なくとも 1種以上を添加することによって、より高い硬度としながらも良 好な崩壊性が得られることがわかる。 [0118] From the results of Table 5, it is preferable to add at least one selected from the group consisting of excipient, disintegration aid and Z or binder force to the granulated particles of the present invention, while achieving higher hardness. It can be seen that disintegration is obtained.
[0119] [参考例 6] 造粒粒子の製造 [0119] [Reference Example 6] Production of granulated particles
マン-トール〔マンニット p、東和化成工業 (株)製〕 63重量部、キシリトール 6重量部 、クロスポビドン 7重量部、結晶セルロース 19重量部、メタケイ酸アルミン酸マグネシゥ ム 5重量部を水に均質に分散させたのち、噴霧乾燥機〔L— 8型、大川原化工機 (株) 製〕を用いて、出口温度 90°Cで噴霧乾燥し、流動性の良!、白色の球状の造粒粒子 を得た。 Mantol (Mannit p, manufactured by Towa Kasei Kogyo Co., Ltd.) 63 parts by weight, 6 parts by weight of xylitol, 7 parts by weight of crospovidone, 19 parts by weight of crystalline cellulose, 5 parts by weight of magnesium metasilicate aluminate in water And then spray-dried at an outlet temperature of 90 ° C using a spray dryer (L-8 type, manufactured by Okawara Kako Co., Ltd.). Good fluidity! White spherical granulated particles Got.
[0120] [比較例 16] [0120] [Comparative Example 16]
参考例 6で得られた造粒粒子 70重量部にァスコルビン酸 30重量部を混合し、適量 のステアリン酸マグネシウムを混合したのち、ロータリー打錠機により設定硬度 50Nと して打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た。 After mixing 70 parts by weight of the granulated particles obtained in Reference Example 6 with 30 parts by weight of ascorbic acid and mixing an appropriate amount of magnesium stearate, the tablet is tableted with a set hardness of 50 N using a rotary tableting machine, and the weight is 200 mg. A tablet with a diameter of 8 mm and 9R was obtained.
[0121] [実施例 50] [0121] [Example 50]
参考例 6で得られた造粒粒子 40重量部にァスコルビン酸 30重量部とコメデンプン 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー打 錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得た
[0122] [実施例 51] 40 parts by weight of the granulated particles obtained in Reference Example 6 were mixed with 30 parts by weight of ascorbic acid and 30 parts by weight of rice starch, mixed with an appropriate amount of magnesium stearate, and then tableted using a rotary tableting machine with a set hardness of 50N. And obtained tablets with a weight of 200 mg, a diameter of 8 mm and 9R [0122] [Example 51]
参考例 6で得られた造粒粒子 40重量部にァスコルビン酸 30重量部とコメデンプン 20重量部とトウモロコシデンプン 10重量部を混合し、適量のステアリン酸マグネシゥ ムを混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg 、直径 8mmゝ 9Rの錠剤を得た。 After mixing 40 parts by weight of the granulated particles obtained in Reference Example 6 with 30 parts by weight of ascorbic acid, 20 parts by weight of rice starch and 10 parts by weight of corn starch, and mixing an appropriate amount of magnesium stearate, a rotary tableting machine is used. Was tableted with a set hardness of 50 N, and tablets with a weight of 200 mg and a diameter of 8 mm 9 R were obtained.
[0123] [実施例 52] [0123] [Example 52]
参考例 6で得られた造粒粒子 40重量部にァスコルビン酸 30重量部とコメデンプン 20重量部と結晶セルロース 10重量部を混合し、適量のステアリン酸マグネシウムを 混合したのち、ロータリー打錠機により設定硬度 50Nとして打錠し、重量 200mg、直 径 8mmゝ 9Rの錠剤を得た。 After mixing 40 parts by weight of the granulated particles obtained in Reference Example 6 with 30 parts by weight of ascorbic acid, 20 parts by weight of rice starch and 10 parts by weight of crystalline cellulose, and mixing an appropriate amount of magnesium stearate, a rotary tableting machine is used. Tableting was performed with a set hardness of 50 N, and tablets with a weight of 200 mg and a diameter of 8 mm ゝ 9R were obtained.
[0124] [実施例 53] [0124] [Example 53]
参考例 6で得られた造粒粒子 40重量部にァスコルビン酸 30重量部と結晶背セル口 ース 30重量部を混合し、適量のステアリン酸マグネシウムを混合したのち、ロータリー 打錠機により設定硬度 50Nとして打錠し、重量 200mg、直径 8mm、 9Rの錠剤を得 た。 Mix 40 parts by weight of the granulated particles obtained in Reference Example 6 with 30 parts by weight of ascorbic acid and 30 parts by weight of crystal back cell mouth, mix an appropriate amount of magnesium stearate, and then set the hardness using a rotary tableting machine. Tableting was performed as 50N to obtain tablets having a weight of 200 mg, a diameter of 8 mm, and 9R.
[0125] [表 6] [0125] [Table 6]
[0126] 表 6の結果より、本発明における造粒粒子に賦形剤、崩壊助剤及び Z又は結合剤 力 選ばれる少なくとも 1種以上を添加することによって、より高い硬度としながらも良 好な崩壊性が得られることがわかる。 [0126] From the results shown in Table 6, it is preferable to add at least one selected from the group consisting of an excipient, a disintegration aid, and Z or a binder force to the granulated particles of the present invention, while attaining a higher hardness. It can be seen that disintegration is obtained.
[0127] [参考例 7] 造粒粒子の製造 [0127] [Reference Example 7] Production of granulated particles
マン-トール 65重量部、乳糖 5重量部、クロスポビドン 8重量部、結晶セルロース 18 重量部、リン酸水素カルシウム 4重量部を水に均質に分散させたのち、噴霧乾燥機〔 L— 8型、大川原化工機 (株)製〕を用いて、出口温度 90°Cで噴霧乾燥し、流動性の
良 ヽ白色の球状の粒子を得た。 After uniformly dispersing 65 parts by weight of Mantol, 5 parts by weight of lactose, 8 parts by weight of crospovidone, 18 parts by weight of crystalline cellulose, and 4 parts by weight of calcium hydrogen phosphate, the spray dryer [L-8 type, Okawara Kako Co., Ltd.) and spray dried at an outlet temperature of 90 ° C. Good white spherical particles were obtained.
[0128] [比較例 17] [0128] [Comparative Example 17]
参考例 7で得られた造粒粒子 80重量部、アスピリン 20重量部及び適量の適量のス テアリン酸マグネシウムを混合したのち、打錠機〔小型高速回転式打錠機 VIRGO, (株)菊水製作所製〕を用いて打錠し、錠剤重量 200mg、直径 8mm、平スミ角の錠 剤を得た。 After mixing 80 parts by weight of the granulated particles obtained in Reference Example 7, 20 parts by weight of aspirin and an appropriate amount of magnesium stearate, a tableting machine (compact high-speed rotary tableting machine VIRGO, Kikusui Manufacturing Co., Ltd.) To obtain a tablet with a tablet weight of 200 mg, a diameter of 8 mm and a flat corner.
[0129] [実施例 54] [Example 54]
参考例 7で得られた造粒粒子 80重量部に対して、アスピリン 20重量部を混合し、 顆粒を打錠機の臼に充填する前に適量のステアリン酸マグネシウムを杵表面および 臼壁に塗布する装置を装着した外部滑沢装置付き打錠機〔小型高速回転式打錠機 VIRGO, (株)菊水製作所製〕を用いて打錠し、錠剤重量 200mg、直径 8mm、平ス ミ角の錠剤を製造した。 20 parts by weight of aspirin is mixed with 80 parts by weight of the granulated particles obtained in Reference Example 7, and an appropriate amount of magnesium stearate is applied to the surface of the punch and the wall of the die before filling the granules into the die of the tablet machine. Tablet with external lubrication device (compact high-speed rotary tableting machine VIRGO, manufactured by Kikusui Seisakusho Co., Ltd.), tablet weight 200mg, diameter 8mm, flat corner angle tablet Manufactured.
[0130] [表 7] [0130] [Table 7]
[0131] 表 7の結果より、外部滑沢法により打錠した口腔内速崩壊性錠剤は良好な成形性 · 崩壊性が得られ、予め滑沢剤と混合し打錠した口腔内速崩壊性錠剤よりも、崩壊時 間が短ぐ崩壊性が優れていることがわかる。 [0131] From the results in Table 7, oral disintegrating tablets that were tableted by the external lubrication method obtained good moldability and disintegration, and were rapidly mixed with the lubricant and tableted in advance. It can be seen that the disintegration time is shorter than tablets, and the disintegration is superior.
産業上の利用可能性 Industrial applicability
[0132] 充分な硬度を有し、口腔内での良好な崩壊性を有する錠剤として提供することができ る。 [0132] It can be provided as a tablet having sufficient hardness and good disintegration property in the oral cavity.
活性成分の含有率が高い場合に生じる問題がなぐまた、製造や輸送に欠けや粉化 t 、つた問題が生じな!/、程度の充分な硬度と高!、成形性を有しながら、良好な口腔 内での崩壊性を有する口腔内速崩壊錠、ならびに通常の製剤設備を用いて圧縮成 型することに得る口腔内速崩壊錠の製法を提供することができる。
There are no problems that occur when the content of the active ingredient is high. In addition, there are no problems in manufacturing and transportation, and there are no problems! /, Sufficient hardness and high degree, and good moldability. It is possible to provide a method for producing an intraoral rapidly disintegrating tablet having a disintegrating property in the oral cavity and an intraoral rapidly disintegrating tablet obtained by compression molding using an ordinary preparation facility.
Claims
[1] (a) (ィ) 2種以上の糖類の複合粒子中に、(口)無機物及び (ハ)崩壊剤が均質に分 散してなる造粒粒子、(b)滑沢剤、(c)賦形剤、崩壊助剤及び Z又は結合剤から選 ばれる少なくとも 1種以上、及び (d)活性成分からなる口腔内速崩壊性錠剤。 [1] (a) (i) Granulated particles in which (mouth) inorganic substance and (c) disintegrant are uniformly dispersed in composite particles of two or more saccharides, (b) lubricant, ( c) An orally rapidly disintegrating tablet comprising at least one selected from excipients, disintegration aids and Z or binders, and (d) an active ingredient.
[2] 造粒粒子の糖類が、マン-トールと下記の群力 選ばれる少なくとも 1種以上力 な る複合粒子である請求項 1の口腔内速崩壊性錠剤; [2] The intraorally rapidly disintegrating tablet according to claim 1, wherein the saccharide of the granulated particles is a composite particle having at least one kind selected from mannitol and the following group force;
キシリトール、ソルビトール、エリスリトール、マルチトール、乳糖、ショ糖、ブドウ糖、果 糖、麦芽糖、トレハロース、パラチニットおよびパラチノース。 Xylitol, sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, palatinit and palatinose.
[3] 造粒粒子の無機物力 メタケイ酸アルミン酸マグネシウム、ケィ酸アルミン酸マグネシ ゥム、リン酸水素カルシウム、無水リン酸水素カルシウム、無水リン酸水素カルシウム 造粒物、ノ、イド口タルサイト、ケィ酸アルミニウム、リン酸カルシウム、炭酸カルシウム、 ケィ酸カルシウム、ケィ酸マグネシウム、酸化マグネシウム、水酸化マグネシウム、水 酸ィ匕アルミナマグネシウム、乾燥水酸ィ匕アルミニウムゲル、炭酸マグネシウム力も選 ばれる少なくとも 1種以上力もなる、請求項 1〜2の口腔内速崩壊性錠剤。 [3] Inorganic strength of granulated particles Magnesium aluminate metasilicate, magnesium aluminate silicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate Aluminum Calcium Phosphate, Calcium Phosphate, Calcium Carbonate, Calcium Kaate, Magnesium Oxide, Magnesium Oxide, Magnesium Hydroxide, Hydroxy-Alumina Magnesium, Dry Hydroxy-Aluminum Gel, Magnesium Carbonate The orally rapidly disintegrating tablet according to claim 1 or 2.
[4] 造粒粒子の崩壊剤が、クロスポビドン、低置換度ヒドロキシプロピルセルロース、結晶 セルロースおよびクロスカルメロースナトリウム力 選ばれる少なくとも 1種以上力 な る、請求項 1〜3の口腔内速崩壊性錠剤。 [4] The intraoral fast disintegrating property according to claims 1 to 3, wherein the disintegrant of the granulated particles is at least one selected from crospovidone, low-substituted hydroxypropylcellulose, crystalline cellulose and croscarmellose sodium strength. tablet.
[5] 請求項 1〜4の造粒粒子の各成分力 (ィ)糖類 40〜90重量部、(口)無機物 1〜30 重量部、(ハ)崩壊剤 5〜40重量部であって、成分 (ィ)〜 (ハ)の総量が 100重量部 からなり、(ィ)の糖類がマン-トール:マン-トール以外の糖類 = 98〜67: 2〜33の 割合カゝらなる造粒粒子を含む請求項 1〜4の口腔内速崩壊性錠剤。 [5] Each component force of the granulated particles according to claims 1 to 4 (i) 40 to 90 parts by weight of sugar, (mouth) 1 to 30 parts by weight of an inorganic substance, (c) 5 to 40 parts by weight of a disintegrant, The total amount of ingredients (ii) to (iii) consists of 100 parts by weight, and the saccharide of (ii) is a granulated particle with a ratio of saccharides other than mantol: mannitol = 98 to 67: 2 to 33 The intraorally rapidly disintegrating tablet according to claim 1, comprising:
[6] 請求項 1〜4の造粒粒子の各成分力 (ィ)糖類 50〜80重量部、(口)無機物 2〜15 重量部、(ハ)崩壊剤 10〜36重量部であって、成分 (ィ)〜 (ハ)の総量が 100重量部 からなり、(ィ)の糖類がマン-トール:マン-トール以外の糖類= 97〜87 : 3〜13の 割合カゝらなる造粒粒子を含む請求項 1〜4の口腔内速崩壊性錠剤。 [6] Each component force of the granulated particles of claims 1 to 4 (i) 50 to 80 parts by weight of sugar, (mouth) 2 to 15 parts by weight of an inorganic substance, and (c) 10 to 36 parts by weight of a disintegrant. The total amount of ingredients (i) to (c) is 100 parts by weight, and the saccharide of (i) is a granulated particle with a ratio of saccharides other than mantol: saccharides other than mantol = 97 to 87: 3 to 13 The intraorally rapidly disintegrating tablet according to claim 1, comprising:
[7] 請求項 1〜4の造粒粒子の各成分が、(ィ)糖類 62〜78重量部、(口)無機物 3〜8重 量部、(ハ)崩壊剤 18〜34重量部であって、成分 (ィ)〜 (ハ)の総量が 100重量部か らなり、(ィ)の糖類がマン-トール:マン-トール以外の糖類 = 96〜89: 4〜 11の割
合力ゝらなる造粒粒子を含む請求項 1〜4の口腔内速崩壊性錠剤。 [7] The components of the granulated particles according to claims 1 to 4 are (i) 62 to 78 parts by weight of sugar, (mouth) 3 to 8 parts by weight of an inorganic substance, and (c) 18 to 34 parts by weight of a disintegrant. The total amount of components (i) to (c) is 100 parts by weight, and the saccharide of (i) is a saccharide other than man-tol: mann-tol = 96-89: 4-11 The intraorally rapidly disintegrating tablet according to claim 1, comprising granulated particles having a resultant force.
[8] 請求項 1〜7の造粒粒子が、(ィ) 2種以上の糖類、(口)無機物及び (ハ)崩壊剤を水 に懸濁させたのち、噴霧乾燥して得られる造粒粒子である請求項 1〜7の口腔内速 崩壊性錠剤。 [8] The granulated particles according to claims 1 to 7, wherein the granulated particles are obtained by suspending (i) two or more saccharides, (mouth) inorganic substances, and (c) disintegrants in water, followed by spray drying. The intraoral rapidly disintegrating tablet according to claim 1, which is a particle.
[9] 請求項 1〜8の造粒粒子が、活性成分を含む造粒粒子である請求項 1〜8の口腔内 速崩壊性錠剤。 [9] The rapidly disintegrating tablet in an oral cavity according to claims 1 to 8, wherein the granulated particles according to claims 1 to 8 are granulated particles containing an active ingredient.
[10] 滑沢剤が、ステアリン酸、ステアリン酸マグネシウム、ステアリン酸カルシウム、ショ糖 脂肪酸エステル、グリセリン脂肪酸エステル、ポリエチレングリコール、フマル酸ステア リルナトリウム、タルク力 選ばれる少なくとも 1種以上である請求項 1〜9の口腔内速 崩壊性錠剤。 [10] The lubricant is at least one selected from stearic acid, magnesium stearate, calcium stearate, sucrose fatty acid ester, glycerin fatty acid ester, polyethylene glycol, sodium stearyl fumarate, and talc power. 9 intraoral fast disintegrating tablets.
[11] 賦形剤が、粉末セルロース、メタケイ酸アルミン酸マグネシウム、ケィ酸アルミン酸マ グネシゥム、リン酸水素カルシウム、無水リン酸水素カルシウム、無水リン酸水素カル シゥム造粒物、ハイド口タルサイト、ベントナイト、ケィ酸アルミニウム、合成ケィ酸アル ミニゥム 'ヒドロキシプロピルスターチ '結晶セルロース、リン酸カルシウム、炭酸カルシ ゥム、ケィ酸カルシウム、ケィ酸マグネシウム、酸化マグネシウム、水酸化マグネシウム 、水酸ィ匕アルミナマグネシウム、乾燥水酸ィ匕アルミニウムゲル、炭酸マグネシウム、マ ン-トール、キシリトール、ソルビトール、エリスリトール、マルチトール、乳糖、白糖、 ブドウ糖、果糖、麦芽糖、トレハロース、パラチニット、パラチノース、カンテン、セラック 、トラガントから選ばれる少なくとも 1種以上である請求項 1〜10の口腔内速崩壊性錠 剤。 [11] The excipient is powdered cellulose, magnesium aluminate metasilicate, magnesium aluminate silicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, anhydrous calcium phosphate granule, hydrated talcite, Bentonite, Aluminum silicate, Synthetic aluminum silicate 'Hydroxypropyl starch' Crystalline cellulose, Calcium phosphate, Calcium carbonate, Calcium silicate, Magnesium silicate, Magnesium oxide, Magnesium hydroxide, Hydroxy-alumina magnesium, Dry water Acid aluminum gel, magnesium carbonate, mannitol, xylitol, sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, palatinit, palatinose, agar, shellac, tragacanth Et intraorally rapidly disintegrating tablet agent of claim 1 to 10 is at least one selected.
[12] 崩壊助剤が、結晶セルロース、結晶セルロース 'カルメロースナトリウム、カルメロース 、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、クロスポビドン、 低置換度ヒドロキシプロピルセルロース、含水二酸化ケイ素、軽質無水ケィ酸、コムギ デンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、部分アルファ一 化デンプン、ヒドロキシプロピルスターチから選ばれる少なくとも 1種以上である請求 項 1〜11の口腔内速崩壊性錠剤。 [12] Disintegration aids are crystalline cellulose, crystalline cellulose 'carmellose sodium, carmellose, croscarmellose sodium, carboxymethyl starch sodium, crospovidone, low-substituted hydroxypropylcellulose, hydrous silicon dioxide, light anhydrous key acid, wheat The orally rapidly disintegrating tablet according to claim 1, wherein the tablet is at least one selected from starch, rice starch, corn starch, potato starch, partially alpha starch, and hydroxypropyl starch.
[13] 結合剤が、カルメロースナトリウム、ヒドロキシプロピルセルロース、ヒドロキシプロピル メチルセルロース、ポリビュルピロリドン、アラビアゴム末、ゼラチン、プルランカゝら選ば
れる少なくとも 1種以上である請求項 1〜 12の口腔内速崩壊性錠剤。 [13] Binder selected from carmellose sodium, hydroxypropylcellulose, hydroxypropyl methylcellulose, polybulurpyrrolidone, gum arabic powder, gelatin, pullulan, etc. The orally rapidly disintegrating tablet according to claim 1, wherein the tablet is at least one or more kinds.
[14] 錠剤全体 100重量部に対して、(a)造粒粒子 1〜98重量部、(b)滑沢剤 0. 01〜5重 量部、(c)賦形剤、崩壊助剤及び Z又は結合剤力 選ばれる少なくとも 1種以上 1〜 98重量部、(d)活性成分 0. 01〜60重量部力もなる請求項 1〜13の口腔内速崩壊 性錠剤。 [14] For 100 parts by weight of the whole tablet, (a) 1 to 98 parts by weight of granulated particles, (b) 0.01 to 5 parts by weight of lubricant, (c) excipient, disintegration aid and 14. Orally rapidly disintegrating tablet according to claim 1 to 13, wherein at least one or more selected from 1 to 98 parts by weight, (d) active ingredient is also added to 0.01 to 60 parts by weight.
[15] 錠剤全体 100重量部に対して、(a)造粒粒子 5〜90重量部、(b)滑沢剤 0. 01〜3重 量部、(c)賦形剤、崩壊助剤及び Z又は結合剤力 選ばれる少なくとも 1種以上 5〜 90重量部、(d)活性成分 0. 1〜50重量部力もなる請求項 1〜13の口腔内速崩壊性 錠剤。 [15] Based on 100 parts by weight of the whole tablet, (a) 5 to 90 parts by weight of granulated particles, (b) 0.01 to 3 parts by weight of lubricant, (c) excipient, disintegration aid and The orally fast disintegrating tablet according to any one of claims 1 to 13, comprising at least one or more selected from Z or binder power of 5 to 90 parts by weight, and (d) active ingredient of 0.1 to 50 parts by weight.
[16] (a)造粒粒子、 (b)滑沢剤、 (c)賦形剤、崩壊助剤及び Z又は結合剤から選ばれる 少なくとも 1種以上、及び (d)活性成分を混合したのち圧縮成型してなる請求項 1〜1 5の口腔内速崩壊性錠剤の製法。 [16] After mixing (a) granulated particles, (b) lubricant, (c) at least one selected from excipients, disintegration aids and Z or binders, and (d) active ingredients The method for producing an orally rapidly disintegrating tablet according to claim 1 to 15, which is compression-molded.
[17] 圧縮成型機の杵表面、臼壁面に予め (b)滑沢剤を塗布し、(a)造粒粒子、(c)賦形 剤、崩壊助剤及び Z又は結合剤カゝら選ばれる少なくとも 1種以上、及び (d)活性成 分を混合'充填し圧縮成型してなる請求項 1〜15の口腔内速崩性壊錠剤の製法。
[17] (b) Lubricant applied in advance to the mortar surface and mortar wall of the compression molding machine, and (a) granulated particles, (c) excipient, disintegration aid and Z or binder selected. The method for producing an orally rapidly disintegrating tablet according to claim 1, wherein at least one or more selected from the above and (d) active ingredients are mixed and filled and compression molded.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007534257A JP5074190B2 (en) | 2005-09-02 | 2006-05-16 | Orally rapidly disintegrating tablets |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-254478 | 2005-09-02 | ||
JP2005254478 | 2005-09-02 | ||
JP2005-364009 | 2005-12-16 | ||
JP2005364009 | 2005-12-16 | ||
JP2006-042944 | 2006-02-20 | ||
JP2006042944 | 2006-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007029376A1 true WO2007029376A1 (en) | 2007-03-15 |
Family
ID=37835510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/309706 WO2007029376A1 (en) | 2005-09-02 | 2006-05-16 | Orally rapidly disintegrating tablet |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5074190B2 (en) |
WO (1) | WO2007029376A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008285434A (en) * | 2007-05-16 | 2008-11-27 | Taisho Pharm Ind Ltd | Orally disintegrating tablets |
JP2010143836A (en) * | 2008-12-16 | 2010-07-01 | Nichi-Iko Pharmaceutical Co Ltd | Composition for orally disintegrable tablet |
WO2010092828A1 (en) | 2009-02-12 | 2010-08-19 | 富士化学工業株式会社 | Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same |
JP2010241695A (en) * | 2009-04-01 | 2010-10-28 | Teika Seiyaku Kk | Oral rapidly disintegrating tablet and method for producing the same |
JP2011026311A (en) * | 2009-06-29 | 2011-02-10 | Fuji Chem Ind Co Ltd | Method for producing tablet quickly disintegrating in oral cavity |
WO2011019046A1 (en) | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
WO2011019045A1 (en) | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
WO2011019043A1 (en) | 2009-08-11 | 2011-02-17 | 大日本住友製薬株式会社 | Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles |
JP2011513194A (en) * | 2008-02-29 | 2011-04-28 | 大塚製薬株式会社 | Orally disintegrating tablets |
JP2011524386A (en) * | 2008-06-20 | 2011-09-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Direct compressible and fast disintegrating tablet matrix |
US8613950B2 (en) | 2005-03-01 | 2013-12-24 | Bayer Intellectual Property Gmbh | Pharmaceutical forms with improved pharmacokinetic properties |
WO2014014010A1 (en) | 2012-07-20 | 2014-01-23 | 大塚製薬株式会社 | Tablet having dry-ink film on surface thereof, and ink for inkjet printer |
US8841446B2 (en) | 2002-07-16 | 2014-09-23 | Bayer Intellectual Property Gmbh | Medicaments containing vardenafil hydrochloride trihydrate |
US9284490B2 (en) | 2010-10-28 | 2016-03-15 | National Institute For Materials Science | Organic/inorganic hybrids, and process of producing them |
JP2017071561A (en) * | 2015-10-05 | 2017-04-13 | 大同化成工業株式会社 | Compound granulated product containing sugar or sugar alcohol, swelling binder, disintegrant and superabsorbent excipient, and production method thereof |
CN115486543A (en) * | 2022-10-09 | 2022-12-20 | 江苏天美健大自然生物工程有限公司 | High-concentration spirulina tablet and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000078292A1 (en) * | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Quickly disintegrating solid preparations |
WO2002069934A1 (en) * | 2001-03-06 | 2002-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Preparations quickly disintegrating in oral cavity |
WO2005037254A1 (en) * | 2003-10-15 | 2005-04-28 | Fuji Chemical Industry Co., Ltd. | Tablet quickly disintegrating in oral cavity |
WO2005037319A1 (en) * | 2003-10-15 | 2005-04-28 | Fuji Chemical Industry Co., Ltd. | Composition for tablet rapidly disintegrable in mouth |
-
2006
- 2006-05-16 JP JP2007534257A patent/JP5074190B2/en active Active
- 2006-05-16 WO PCT/JP2006/309706 patent/WO2007029376A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000078292A1 (en) * | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Quickly disintegrating solid preparations |
WO2002069934A1 (en) * | 2001-03-06 | 2002-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Preparations quickly disintegrating in oral cavity |
WO2005037254A1 (en) * | 2003-10-15 | 2005-04-28 | Fuji Chemical Industry Co., Ltd. | Tablet quickly disintegrating in oral cavity |
WO2005037319A1 (en) * | 2003-10-15 | 2005-04-28 | Fuji Chemical Industry Co., Ltd. | Composition for tablet rapidly disintegrable in mouth |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841446B2 (en) | 2002-07-16 | 2014-09-23 | Bayer Intellectual Property Gmbh | Medicaments containing vardenafil hydrochloride trihydrate |
US8613950B2 (en) | 2005-03-01 | 2013-12-24 | Bayer Intellectual Property Gmbh | Pharmaceutical forms with improved pharmacokinetic properties |
JP2008285434A (en) * | 2007-05-16 | 2008-11-27 | Taisho Pharm Ind Ltd | Orally disintegrating tablets |
JP2011513194A (en) * | 2008-02-29 | 2011-04-28 | 大塚製薬株式会社 | Orally disintegrating tablets |
US11166917B2 (en) | 2008-06-20 | 2021-11-09 | Merck Patent Gmbh | Direct injection moldable and rapidly disintegrating tablet matrix |
JP2011524386A (en) * | 2008-06-20 | 2011-09-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Direct compressible and fast disintegrating tablet matrix |
JP2010143836A (en) * | 2008-12-16 | 2010-07-01 | Nichi-Iko Pharmaceutical Co Ltd | Composition for orally disintegrable tablet |
WO2010092828A1 (en) | 2009-02-12 | 2010-08-19 | 富士化学工業株式会社 | Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same |
JP2010241695A (en) * | 2009-04-01 | 2010-10-28 | Teika Seiyaku Kk | Oral rapidly disintegrating tablet and method for producing the same |
JP2011026311A (en) * | 2009-06-29 | 2011-02-10 | Fuji Chem Ind Co Ltd | Method for producing tablet quickly disintegrating in oral cavity |
US9446055B2 (en) | 2009-08-11 | 2016-09-20 | Fuji Chemical Industry Co., Ltd. | Disintegrating particle composition and orally rapidly disintegrating tablet |
WO2011019045A1 (en) | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
WO2011019046A1 (en) | 2009-08-11 | 2011-02-17 | 富士化学工業株式会社 | Disintegrating particle composition and orally rapidly disintegrating tablet |
WO2011019043A1 (en) | 2009-08-11 | 2011-02-17 | 大日本住友製薬株式会社 | Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles |
US8900602B2 (en) | 2009-08-11 | 2014-12-02 | Fuji Chemical Industry Co., Ltd. | Disintegrating particle composition and orally rapidly disintegrating tablet |
JP5674666B2 (en) * | 2009-08-11 | 2015-02-25 | 富士化学工業株式会社 | Disintegrating particle composition and intraoral quick disintegrating tablet |
JP5674667B2 (en) * | 2009-08-11 | 2015-02-25 | 富士化学工業株式会社 | Disintegrating particle composition and intraoral quick disintegrating tablet |
US8591955B2 (en) | 2009-08-11 | 2013-11-26 | Dainippon Sumitomo Pharma Co., Ltd. | Orally rapidly disintegrating tablet that contains two or more types of particles |
US9284490B2 (en) | 2010-10-28 | 2016-03-15 | National Institute For Materials Science | Organic/inorganic hybrids, and process of producing them |
WO2014014010A1 (en) | 2012-07-20 | 2014-01-23 | 大塚製薬株式会社 | Tablet having dry-ink film on surface thereof, and ink for inkjet printer |
JP2017071561A (en) * | 2015-10-05 | 2017-04-13 | 大同化成工業株式会社 | Compound granulated product containing sugar or sugar alcohol, swelling binder, disintegrant and superabsorbent excipient, and production method thereof |
WO2017061426A1 (en) * | 2015-10-05 | 2017-04-13 | 大同化成工業株式会社 | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product |
US10632074B2 (en) | 2015-10-05 | 2020-04-28 | Daido Chemical Corporation | Composite granulated product including sugar or sugar alcohol, swelling binder, disintegrating agent and highly absorbent excipient, and method for manufacturing composite granulated product |
CN115486543A (en) * | 2022-10-09 | 2022-12-20 | 江苏天美健大自然生物工程有限公司 | High-concentration spirulina tablet and preparation method thereof |
CN115486543B (en) * | 2022-10-09 | 2024-02-23 | 江苏天美健大自然生物工程有限公司 | High-concentration spirulina tablet and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5074190B2 (en) | 2012-11-14 |
JPWO2007029376A1 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5074190B2 (en) | Orally rapidly disintegrating tablets | |
JP3841804B2 (en) | Composition for intraorally rapidly disintegrating tablets | |
CN101283991B (en) | Orally-disintegrating tablet and manufacturing method thereof | |
EP2218443B1 (en) | Orally disintegrating tablet | |
JP4706785B2 (en) | Particulate pharmaceutical composition for oral administration | |
JP4920798B2 (en) | Intraoral quick disintegrating tablet containing two or more kinds of particles | |
CN102046147B (en) | Pharmaceutical formulations for the manufacture of rapidly disintegrating tablets | |
JP4802436B2 (en) | Orally disintegrating composition and orally disintegrating preparation | |
WO2005037254A1 (en) | Tablet quickly disintegrating in oral cavity | |
CN102772379A (en) | Orally-dispersible multilayer tablet | |
CN1225017A (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
WO2007074856A1 (en) | Method of producing solid preparation disintegrating in the oral cavity | |
JP2009114113A (en) | Intraorally disintegrable tablet and method for producing the same | |
KR20030094272A (en) | Tablets quickly disintegrating in oral cavity | |
JP5534004B2 (en) | Orally disintegrating tablets | |
JP5342028B2 (en) | Orally disintegrating tablets | |
JP2016174616A (en) | Disintegrable composition, and easily disintegrable compression molding | |
JP2002255796A (en) | Rapidly disintegrating tablet in oral cavity and method for producing the same | |
JP2004315483A (en) | Orally disintegrating tablet | |
JP5835875B2 (en) | Method for producing intraorally rapidly disintegrating tablets | |
JPH1143429A (en) | Solid preparation | |
JP5572321B2 (en) | Orally disintegrating tablets containing coated fine particles | |
JP6513702B2 (en) | Super fast disintegrating tablet and method for producing the same | |
JP4601271B2 (en) | COMPRESSION MOLDING AND METHOD FOR PRODUCING THE SAME | |
JP2002308760A (en) | Compression molding composition and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007534257 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06746420 Country of ref document: EP Kind code of ref document: A1 |